Anti-IL1RAP antibodies and antibody drug conjugates
By developing high-affinity anti-IL1RAP antibodies and antibody drug conjugates, binding and inducing IL1RAP cell death, the problem of lack of effective anti-IL1RAP antibodies in the prior art is solved, and a novel anti-IL1R helper protein is provided Cancer treatment methods.
Patent Information
- Application Number
- CN202410992202.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-06-12
- Filing Date
- 2018-06-12
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has not yet provided effective anti-IL1RAP antibodies and antibody drug conjugates (ADCs) for cancer treatment and cannot effectively target the role of IL-1R adjuvant proteins in cancer.
An anti-IL1RAP antibody and its antibody drug conjugate were developed to achieve high affinity (Kd binding in the range of 1 nM to 0.001 nM) by binding to the external domain of IL1RAP and able to be internalized or induce cell death. An antibody or its antigen-binding portion comprises specific heavy and light chain variable region amino acid sequences for specific binding and acting on IL1RAP.
The efficient binding and cell death induction of IL1RAP are achieved, providing a new anti-cancer treatment method, which can target the role of IL-1R auxiliary protein in cancer and improve the therapeutic effect.
Smart Images

Figure CN118994394A_ABST
Abstract
Description
[0001] This application is a divisional application of the patent application entitled “Anti-IL1RAP Antibodies and Antibody-Drug Conjugates” and application number 201880052046.4.
[0002] Related applications
[0003] This application claims priority to U.S. Provisional Application No. 62 / 518,069, filed on June 12, 2017, the entire contents of which are expressly incorporated herein by reference.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted electronically in ASCII format, the entire contents of which are incorporated herein by reference. The ASCII copy was created on June 12, 2018, is named 127913-00820_SL.txt, and is 163,057 bytes in size. Background Art
[0006] IL1RAP, also known as "interleukin 1 receptor accessory protein," "IL-1R accessory protein," "IL-1 receptor accessory protein," "interleukin-1 receptor 3," "IL-1RAcP," "C3orf13," "IL-1R3," "IL1R3," "interleukin-1 receptor accessory protein β," "interleukin-1 receptor accessory protein," and "IL-1R-3" (Wesche, H., J. Biol. Chem. 272:7727-7731, 1997), is an essential part of the interleukin 1 (IL-1) receptor complex that initiates signaling events leading to activation of interleukin 1-responsive genes. In addition to IL1 signaling, IL1RAP is crucial for the actions of IL33, mediated by the ST2 / IL1RAP complex, and IL36, mediated by the IL1Rrp2 / IL1RAP complex (Garlanda et al., Immunity. 2013 Dec 12;39(6):1003-18).
[0007] Two IL-1 receptors have been identified, type I IL-1R and type II IL-1R. Both receptors are able to interact with all three forms of IL-1 family molecules. IL-1RI is responsible for mediating IL-1-induced cell activation. However, the IL-1 / IL-1RI complex itself cannot signal, but relies on binding to IL1RAP (Dinarello, CA, Blood 30 1996, 87(6):2095-147) (see, for example, WO 2015 / 132602).
[0008] Alternative splicing of IL1RAP results in the production of two transcript variants encoding two different isoforms, one membrane-bound and one soluble. During acute phase induction or stress, the ratio of the soluble to membrane-bound form increases. IL1RAP is expressed on candidate leukemic stem cells in most AML patients but not on normal hematopoietic stem cells ( et al., PNAS USA (2015) vol.112:34,10786–10791).
[0009] Interleukin-1
[0010] Interleukin 1 (IL-1) is a potent proinflammatory cytokine that can induce acute phase and proinflammatory protein synthesis during infection, tissue damage or stress by forming a complex with the interleukin 1 receptor and accessory proteins on the cell membrane. In response to infection and inflammation, IL-1 can be produced by a variety of cell types, including mononuclear phagocytes. The IL-1 family consists of seven agonists, including IL-1α and IL-1β, and three naturally occurring receptor antagonists, including the IL-1 receptor antagonist (IL-25 1Ra) (Dinarello, CA, Blood 1996, 87(6):2095-147).
[0011] IL-1 can activate several cell types including leukocytes and endothelial cells. IL-1 induces and amplifies immune response by promoting the production and expression of adhesion molecules, cytokines, chemokines and other inflammatory mediators (such as prostaglandin E2 and nitric oxide (NO)). As a result, local inflammation is amplified and sustained. In addition, the generation of inflammatory mediators induced by IL-1 causes fever, headache, hypotension and weight loss. In addition, IL-1 is a hematopoietic growth factor, and has been shown to reduce the lowest point (nadir) of leukocytes and platelets in patients during bone marrow transplantation. IL-1 has also been shown to promote angiogenesis by inducing the production of vascular endothelial growth factor, thereby promoting pannus formation and blood supply in rheumatoid arthritis. Finally, IL-1 has been shown to promote the degradation of bone and cartilage in rheumatic diseases.
[0012] IL-1 is involved in a variety of diseases and conditions, from gout to cancer (for reviews, see Dinarello et al., 2012, Nature Reviews 11:633-652 and Dinarello, 2014, Mol. Med. 20(suppl. 1):S43-S58; the disclosures of which are incorporated herein by reference), including joint, bone, and muscle diseases, such as rheumatoid arthritis and osteoarthritis; inherited systemic autoinflammatory diseases, such as familial Mediterranean fever; systemic autoinflammatory diseases, such as systemic juvenile idiopathic arthritis and adult-onset Still's disease; common inflammatory diseases, such as gout and type 2 diabetes; acute onset ischemic diseases, such as myocardial infarction; and cancer.
[0013] Several therapies that block IL-1 activity have been approved and are under development. Targeting IL-1 began in 1993 with the introduction of anakinra (Kineret TM ; Amgen), which is a recombinant form of the naturally occurring IL-1 receptor antagonist (IL-1Ra) that blocks the activity of both IL-1α and IL-1β. Since then, this therapeutic agent has been used to demonstrate the role of IL-1 in a variety of diseases. Neutralization of IL-1 with antibodies or soluble receptors has also been shown to be effective, and a soluble decoy receptor, rilonacept (Arcalyst®), has been approved. TM ; Regeneron) and the anti-IL-1β neutralizing monoclonal antibody canakinumab (His TM ; Novartis. Other therapeutic approaches (including IL-1α neutralization, therapeutic vaccines targeting IL-1β, and chimeric IL-1Ra) are in clinical trials. In addition, orally active small molecule inhibitors of IL-1 production, such as caspase 1 inhibitors, have been developed.
[0014] Antibody-drug conjugates (ADCs) represent a new class of therapeutics consisting of antibodies conjugated to cytotoxic drugs via chemical linkers. The therapeutic concept of ADCs is to combine the binding capabilities of antibodies with drugs, where the antibodies are used to deliver drugs to tumor cells by binding to target surface antigens.
[0015] Therefore, there remains a need in the art for anti-IL1 RAP antibodies and ADCs that can be used for therapeutic purposes in the treatment of cancer. Summary of the Invention
[0016] In certain aspects, the invention provides anti-IL1RAP antibodies, antigen-binding portions thereof, and antibody drug conjugates (ADCs).In certain aspects of the invention, the antibody or antigen-binding portion thereof binds to IL1RAP (SEQ ID NO: 286) or the extracellular domain of IL1RAP.
[0017] In one embodiment, an antibody or antigen-binding portion thereof of the invention has a K of about 2,000 nM or less, about 1,000 nM or less, about 500 nM or less, about 200 nM or less, about 100 nM or less, about 75 nM or less, about 25 nM or less, about 21 nM or less, about 12 nM or less, about 11 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 0.5 nM or less, about 0.3 nM or less, about 0.1 nM or less, or about 0.01 nM or less, or about 0.001 nM or less. d Binds to IL1RAP.
[0018] In other embodiments of the invention, the anti-IL1RAP antibody drug conjugates (ADCs) of the invention (e.g., IL1RAP antibodies of the invention conjugated to a toxin) are capable of being internalized. In another embodiment, the anti-IL1RAP antibody drug conjugates (ADCs) of the invention are capable of inducing cell death that endogenously expresses IL1RAP.
[0019] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 8.
[0020] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 7. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 6.
[0021] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 16.
[0022] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 11 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 15. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 14.
[0023] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 24.
[0024] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 19 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 23. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 18 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 22.
[0025] In another aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 28 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 31.
[0026] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 27 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 23. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 26 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 30.
[0027] In another aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 35 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 39.
[0028] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 37.
[0029] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 47.
[0030] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 46. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 45.
[0031] In another aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 51 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 55.
[0032] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 50 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 54. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 53.
[0033] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 59 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 63.
[0034] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 58 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 57 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 61.
[0035] In another aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 70.
[0036] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 66 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 65 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 69.
[0037] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 70.
[0038] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 72 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 65 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 69.
[0039] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 77 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 81.
[0040] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 76 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 75 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 79.
[0041] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 16.
[0042] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 11 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 15. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 14.
[0043] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 86 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 89.
[0044] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 85 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 84 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 88.
[0045] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 92 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 95.
[0046] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 91 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 84 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 94.
[0047] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 92 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 99.
[0048] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 97 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 84 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 79.
[0049] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 24.
[0050] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 102 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 105. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 101 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 104.
[0051] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 86 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 89.
[0052] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 107 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 84 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 88.
[0053] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 112 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 39.
[0054] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 111 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 110 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 37.
[0055] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 35 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 39.
[0056] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 115.
[0057] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 35 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 39.
[0058] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 117, and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 37.
[0059] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 70.
[0060] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 119 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 26 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 69.
[0061] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 70.
[0062] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 66 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 101 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 69.
[0063] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 70.
[0064] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 66 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 26 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 69.
[0065] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 67 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 129.
[0066] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 66 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 101 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 69.
[0067] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 133 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 70.
[0068] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 132 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 131 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 135.
[0069] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 51 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 55.
[0070] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 50 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 139. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 138.
[0071] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 142 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 47.
[0072] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 46. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 141 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 45.
[0073] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 150.
[0074] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 146 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 149. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 145 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 148.
[0075] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 157.
[0076] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 153 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 156. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 152 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 155.
[0077] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 162.
[0078] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 159 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 161. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 145 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 148.
[0079] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 166 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 169.
[0080] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 165 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 168. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 164 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 155.
[0081] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 171 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 169.
[0082] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 165 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 168. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 164 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 155.
[0083] In one aspect of the invention, the disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 176 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 179.
[0084] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 175 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 178. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 174 and a light chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 79.
[0085] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 183 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 179.
[0086] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 182 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 80. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 101 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 79.
[0087] In one aspect of the invention, the present disclosure provides an isolated antibody, or antigen-binding portion thereof, that binds to human IL1RAP, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 188 and a light chain variable region comprising a CDR3 having an amino acid sequence of SEQ ID NO: 63.
[0088] In some embodiments, the antibody, or antigen-binding portion thereof, further comprises a heavy chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 187 and a light chain variable region comprising a CDR2 having an amino acid sequence of SEQ ID NO: 62. In other embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 186 and a light chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 190.
[0089] In some aspects, the antibody or its antigen-binding portion thereof is a human antibody or a humanized antibody. In one embodiment, the antibody or its antigen-binding portion thereof is of the IgG isotype. In some embodiments, the antibody or its antigen-binding portion thereof is of the IgG1 isotype. In another embodiment, the antibody or its antigen-binding portion thereof is of the IgG4 isotype. In another embodiment, the antibody or its antigen-binding portion thereof is of the IgG2 isotype. In another embodiment, the antibody or its antigen-binding portion thereof is of the IgG3 isotype.
[0090] In one embodiment, the antibody or antigen binding portion thereof is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). In one embodiment, the antibody or antigen binding portion thereof is unable to induce ADCC.
[0091] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing complement dependent cytotoxicity (CDC).In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing CDC.
[0092] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing ADCC and CDC. In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing ADCC or CDC.
[0093] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, is a multispecific antibody, such as a bispecific antibody.
[0094] In some aspects, the antibody, or antigen-binding portion thereof, has a K of 200 nM or less. D .
[0095] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 4, a CDR2 domain having the amino acid sequence of SEQ ID NO: 3, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 2, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 8, a CDR2 domain having the amino acid sequence of SEQ ID NO: 7, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 6.
[0096] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 12, a CDR2 domain having the amino acid sequence of SEQ ID NO: 11, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 16, a CDR2 domain having the amino acid sequence of SEQ ID NO: 15, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 14.
[0097] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 20, a CDR2 domain having the amino acid sequence of SEQ ID NO: 19, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 18, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 24, a CDR2 domain having the amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 22.
[0098] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 28, a CDR2 domain having the amino acid sequence of SEQ ID NO: 27, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 31, a CDR2 domain having the amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 30.
[0099] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37.
[0100] In one aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 41, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 47, a CDR2 domain having an amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 45.
[0101] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 51, a CDR2 domain having the amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 55, a CDR2 domain having the amino acid sequence of SEQ ID NO: 54, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 53.
[0102] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 59, a CDR2 domain having the amino acid sequence of SEQ ID NO: 58, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 57, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 63, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 61.
[0103] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0104] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 72, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0105] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 77, a CDR2 domain having the amino acid sequence of SEQ ID NO: 76, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 75, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 81, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 79.
[0106] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 86, a CDR2 domain having the amino acid sequence of SEQ ID NO: 85, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 89, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 88.
[0107] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 92, a CDR2 domain having the amino acid sequence of SEQ ID NO: 91, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 95, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 94.
[0108] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 92, a CDR2 domain having the amino acid sequence of SEQ ID NO: 97, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 99, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 79.
[0109] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 20, a CDR2 domain having the amino acid sequence of SEQ ID NO: 102, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 24, a CDR2 domain having the amino acid sequence of SEQ ID NO: 105, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 104.
[0110] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 86, a CDR2 domain having the amino acid sequence of SEQ ID NO: 107, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 89, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 88.
[0111] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 112, a CDR2 domain having the amino acid sequence of SEQ ID NO: 111, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 110, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37.
[0112] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 115.
[0113] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 117, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37.
[0114] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 119, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0115] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0116] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0117] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 129, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69.
[0118] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 133, a CDR2 domain having the amino acid sequence of SEQ ID NO: 132, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 131, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 135.
[0119] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 51, a CDR2 domain having the amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 55, a CDR2 domain having the amino acid sequence of SEQ ID NO: 139, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 138.
[0120] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 142, a CDR2 domain having the amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 141, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 47, a CDR2 domain having the amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 45.
[0121] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 43, a CDR2 domain having the amino acid sequence of SEQ ID NO: 146, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 150, a CDR2 domain having the amino acid sequence of SEQ ID NO: 149, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 148.
[0122] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 43, a CDR2 domain having the amino acid sequence of SEQ ID NO: 153, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 152, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 157, a CDR2 domain having the amino acid sequence of SEQ ID NO: 156, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 155.
[0123] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 43, a CDR2 domain having the amino acid sequence of SEQ ID NO: 159, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 162, a CDR2 domain having the amino acid sequence of SEQ ID NO: 161, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 148.
[0124] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 166, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155.
[0125] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 171, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155.
[0126] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 176, a CDR2 domain having the amino acid sequence of SEQ ID NO: 175, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 174, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 179, a CDR2 domain having the amino acid sequence of SEQ ID NO: 178, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 79.
[0127] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 183, a CDR2 domain having the amino acid sequence of SEQ ID NO: 182, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 181, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 179, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 79.
[0128] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 188, a CDR2 domain having the amino acid sequence of SEQ ID NO: 187, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 186, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 63, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 190.
[0129] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable domain having the amino acid sequence shown in SEQ ID NO: 1 and a light chain variable domain having the amino acid sequence shown in SEQ ID NO: 5.
[0130] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 1, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 1, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 5, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 5.
[0131] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:9 and a light chain variable region having the amino acid sequence of SEQ ID NO:13.
[0132] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:9, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:13, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:13.
[0133] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 17 and a light chain variable region having the amino acid sequence of SEQ ID NO: 21.
[0134] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 17, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 21, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 21.
[0135] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 25 and a light chain variable region having the amino acid sequence of SEQ ID NO: 29.
[0136] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:25, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:25, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:29, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:29.
[0137] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 32 and a light chain variable region having the amino acid sequence of SEQ ID NO: 36.
[0138] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:32, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:32, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:36, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:36.
[0139] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:40 and a light chain variable region having the amino acid sequence of SEQ ID NO:44.
[0140] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:40, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:40, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:44, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:44.
[0141] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:48 and a light chain variable region having the amino acid sequence of SEQ ID NO:52.
[0142] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:48, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:48, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:52, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:52.
[0143] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 56 and a light chain variable region having the amino acid sequence of SEQ ID NO: 60.
[0144] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:56, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:56, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:60, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:60.
[0145] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 64 and a light chain variable region having the amino acid sequence of SEQ ID NO: 68.
[0146] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:64, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:64, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:68, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:68.
[0147] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 71 and a light chain variable region having the amino acid sequence of SEQ ID NO: 73.
[0148] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:71, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:71, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:73, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:73.
[0149] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 74 and a light chain variable region having the amino acid sequence of SEQ ID NO: 78.
[0150] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:74, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:74, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:78, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:78.
[0151] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 9 and a light chain variable region having the amino acid sequence of SEQ ID NO: 82.
[0152] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:9, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:82, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:82.
[0153] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 83 and a light chain variable region having the amino acid sequence of SEQ ID NO: 87.
[0154] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:83, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:83, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:87, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:87.
[0155] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:90 and a light chain variable region having the amino acid sequence of SEQ ID NO:93.
[0156] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:90, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:90, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:93, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:93.
[0157] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:96 and a light chain variable region having the amino acid sequence of SEQ ID NO:98.
[0158] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:96, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:96, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:98, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:98.
[0159] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 100 and a light chain variable region having the amino acid sequence of SEQ ID NO: 103.
[0160] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 100, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 100, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 103, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 103.
[0161] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 106 and a light chain variable region having the amino acid sequence of SEQ ID NO: 108.
[0162] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 106, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 106, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 108, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 108.
[0163] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 109 and a light chain variable region having the amino acid sequence of SEQ ID NO: 113.
[0164] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 109, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 113, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 113.
[0165] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 32 and a light chain variable region having the amino acid sequence of SEQ ID NO: 114.
[0166] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO:32, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:32, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:114, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:114.
[0167] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 116 and a light chain variable region having the amino acid sequence of SEQ ID NO: 36.
[0168] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 116, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 116, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 36, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 36.
[0169] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 118 and a light chain variable region having the amino acid sequence of SEQ ID NO: 120.
[0170] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 118, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 118, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 120, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 120.
[0171] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 121 and a light chain variable region having the amino acid sequence of SEQ ID NO: 122.
[0172] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 121, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 121, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 122, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 122.
[0173] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 123 and a light chain variable region having the amino acid sequence of SEQ ID NO: 124.
[0174] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 123, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 123, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 124, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 124.
[0175] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 125 and a light chain variable region having the amino acid sequence of SEQ ID NO: 126.
[0176] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 125, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 125, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 126, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 126.
[0177] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 127 and a light chain variable region having the amino acid sequence of SEQ ID NO: 128.
[0178] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 127, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 127, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 128, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 128.
[0179] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 130 and a light chain variable region having the amino acid sequence of SEQ ID NO: 134.
[0180] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 130, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 134, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134.
[0181] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 136 and a light chain variable region having the amino acid sequence of SEQ ID NO: 137.
[0182] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 136, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 137, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 137.
[0183] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 140 and a light chain variable region having the amino acid sequence of SEQ ID NO: 143.
[0184] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 140, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 143, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 143.
[0185] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 144 and a light chain variable region having the amino acid sequence of SEQ ID NO: 147.
[0186] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 144, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 144, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 147, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 147.
[0187] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 151 and a light chain variable region having the amino acid sequence of SEQ ID NO: 154.
[0188] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 151, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 154, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154.
[0189] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 158 and a light chain variable region having the amino acid sequence of SEQ ID NO: 160.
[0190] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 158, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 160, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160.
[0191] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 163 and a light chain variable region having the amino acid sequence of SEQ ID NO: 167.
[0192] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 163, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 167, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167.
[0193] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 170 and a light chain variable region having the amino acid sequence of SEQ ID NO: 172.
[0194] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 170, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 170, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 172, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 172.
[0195] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 173 and a light chain variable region having the amino acid sequence of SEQ ID NO: 177.
[0196] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 173, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 173, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 177, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 177.
[0197] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 180 and a light chain variable region having the amino acid sequence of SEQ ID NO: 184.
[0198] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 180, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 180, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 184, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 184.
[0199] In another aspect of the invention, the disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 185 and a light chain variable region having the amino acid sequence of SEQ ID NO: 189.
[0200] In another aspect of the invention, the present disclosure provides an anti-IL1RAP antibody, or an antigen-binding portion thereof, comprising a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 185, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 185, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 189, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 189.
[0201] In another aspect of the invention, the present disclosure provides an antibody, or antigen binding portion thereof, that binds to the same epitope as the antibody, or antigen binding portion thereof, as described herein.
[0202] In another aspect of the invention, the disclosure provides an isolated nucleic acid encoding an antibody, or antigen-binding portion thereof, as described herein.
[0203] In another aspect of the invention, the present disclosure provides a pharmaceutical composition comprising an antibody or antigen-binding portion thereof as described herein, and a pharmaceutically acceptable carrier.
[0204] In another aspect of the invention, the present disclosure provides an antibody, or antigen-binding portion thereof, as described herein, conjugated to at least one drug.
[0205] In some aspects, at least one drug is selected from the following: DNA damaging agents, anti-apoptotic agents, mitotic inhibitors, anti-tumor antibiotics, immunomodulators, nucleic acids for gene therapy, anti-angiogenic agents, antimetabolites, boron-containing agents, chemoprotectants, hormone agents, anti-hormonal agents, corticosteroids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, radiosensitizers, topoisomerase inhibitors and tyrosine kinase inhibitors. In one embodiment, the drug is a DNA damaging agent. In one embodiment, the DNA damaging agent is a PBD.
[0206] In other embodiments, at least one drug is conjugated to the antibody or antigen-binding portion thereof via a linker. In another embodiment, the linker is a cleavable linker. In other embodiments, the linker is a non-cleavable linker.
[0207] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 4, a CDR2 domain having the amino acid sequence of SEQ ID NO: 3, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 2, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 8, a CDR2 domain having the amino acid sequence of SEQ ID NO: 7, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 6.
[0208] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 12, a CDR2 domain having an amino acid sequence of SEQ ID NO: 11, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 16, a CDR2 domain having an amino acid sequence of SEQ ID NO: 15, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 14.
[0209] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 20, a CDR2 domain having the amino acid sequence of SEQ ID NO: 19, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 18, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 24, a CDR2 domain having the amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 22.
[0210] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 28, a CDR2 domain having an amino acid sequence of SEQ ID NO: 27, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 31, a CDR2 domain having an amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 30.
[0211] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 35, a CDR2 domain having an amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 39, a CDR2 domain having an amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 37.
[0212] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 41, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 47, a CDR2 domain having an amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 45.
[0213] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 51, a CDR2 domain having an amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 55, a CDR2 domain having an amino acid sequence of SEQ ID NO: 54, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 53.
[0214] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 59, a CDR2 domain having the amino acid sequence of SEQ ID NO: 58, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 57, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 63, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 61.
[0215] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0216] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 72, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0217] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 77, a CDR2 domain having an amino acid sequence of SEQ ID NO: 76, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 75, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 81, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79.
[0218] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 86, a CDR2 domain having an amino acid sequence of SEQ ID NO: 85, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 89, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 88.
[0219] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 92, a CDR2 domain having the amino acid sequence of SEQ ID NO: 91, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 95, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 94.
[0220] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 92, a CDR2 domain having an amino acid sequence of SEQ ID NO: 97, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 99, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79.
[0221] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 20, a CDR2 domain having an amino acid sequence of SEQ ID NO: 102, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 24, a CDR2 domain having an amino acid sequence of SEQ ID NO: 105, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 104.
[0222] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 86, a CDR2 domain having an amino acid sequence of SEQ ID NO: 107, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 89, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 88.
[0223] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 112, a CDR2 domain having an amino acid sequence of SEQ ID NO: 111, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 110, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 39, a CDR2 domain having an amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 37.
[0224] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 115.
[0225] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 117, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37.
[0226] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 119, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0227] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0228] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0229] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 129, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69.
[0230] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 133, a CDR2 domain having an amino acid sequence of SEQ ID NO: 132, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 131, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 135.
[0231] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 51, a CDR2 domain having an amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 55, a CDR2 domain having an amino acid sequence of SEQ ID NO: 139, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 138.
[0232] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 142, a CDR2 domain having the amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 141, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 47, a CDR2 domain having the amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 45.
[0233] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 146, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 150, a CDR2 domain having an amino acid sequence of SEQ ID NO: 149, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 148.
[0234] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 153, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 152, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 157, a CDR2 domain having an amino acid sequence of SEQ ID NO: 156, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155.
[0235] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 159, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 162, a CDR2 domain having an amino acid sequence of SEQ ID NO: 161, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 148.
[0236] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 166, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155.
[0237] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 171, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155.
[0238] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 176, a CDR2 domain having an amino acid sequence of SEQ ID NO: 175, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 174, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 179, a CDR2 domain having an amino acid sequence of SEQ ID NO: 178, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79.
[0239] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 183, a CDR2 domain having an amino acid sequence of SEQ ID NO: 182, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 181, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 179, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79.
[0240] In another aspect of the invention, the present disclosure provides an antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding portion thereof, conjugated to at least one drug, wherein the antibody, or the antigen-binding portion thereof, comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 188, a CDR2 domain having an amino acid sequence of SEQ ID NO: 187, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 186, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 63, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 190.
[0241] In another aspect of the invention, the present disclosure provides an antibody, or antigen-binding portion thereof, as described herein, conjugated to at least one drug.
[0242] In some embodiments, at least one drug is selected from the following: DNA damaging agents, anti-apoptotic agents, mitotic inhibitors, anti-tumor antibiotics, immunomodulators, nucleic acids for gene therapy, anti-angiogenic agents, antimetabolites, boron-containing agents, chemoprotectants, hormone agents, anti-hormonal agents, corticosteroids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, radiosensitizers, topoisomerase inhibitors and tyrosine kinase inhibitors. In one embodiment, the drug is a DNA damaging agent. In one embodiment, the DNA damaging agent is a PBD.
[0243] In other embodiments, at least one drug is conjugated to the antibody or antigen-binding portion thereof via a linker. In other embodiments, the linker is a cleavable linker. In another embodiment, the linker is a non-cleavable linker.
[0244] In some embodiments, the antibody or its antigen-binding portion thereof is of the IgG1 isotype. In other embodiments, the antibody or its antigen-binding portion thereof is of the IgG4 isotype. In another embodiment, the antibody or its antigen-binding portion thereof is of the IgG2 isotype. In another embodiment, the antibody or its antigen-binding portion thereof is of the IgG3 isotype.
[0245] In another aspect of the present invention, the present disclosure provides a pharmaceutical composition comprising an ADC mixture comprising a plurality of ADCs as described herein, and a pharmaceutically acceptable carrier.
[0246] In some embodiments, the average drug to antibody ratio (DAR) of the ADC mixture is 0-8.
[0247] In another aspect of the invention, the present disclosure provides a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding portion thereof as described herein, or an ADC as described herein.
[0248] In some embodiments, the cancer is acute myeloid leukemia (AML). In other embodiments, the cancer is myelodysplastic syndrome (MDS). In other embodiments, the cancer is NSCLC. In other embodiments, the cancer is ovarian cancer.
[0249] In some embodiments, the present disclosure provides a method for inhibiting or reducing the growth of a solid tumor in a subject having a solid tumor, the method comprising administering to the subject having the solid tumor a therapeutically effective amount of an antibody or antigen-binding portion thereof as described herein, or an ADC as described herein, such that the growth of the solid tumor is inhibited or reduced.
[0250] In some embodiments, the antibody or antigen-binding portion thereof or ADC is administered in combination with an additional agent or additional therapy. In other embodiments, the additional agent is an immune checkpoint inhibitor. In another embodiment, the immune checkpoint inhibitor is an antibody. In another embodiment, the antibody is selected from an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. In other embodiments, the additional therapy is radiation. In another embodiment, the additional agent is a chemotherapeutic agent. In some embodiments, the cancer or tumor is characterized by expression or overexpression of IL1RAP. BRIEF DESCRIPTION OF THE DRAWINGS
[0251] Figure 1 Shown is the surface expression of IL1RAP in the human acute myeloid leukemia cell lines EOL1, Monomac 6, OCI / AML1, and KG-1, and the T-cell leukemia cell line Karpas 299, as determined by flow cytometric analysis.
[0252] Figure 2 Specific binding of the IL1RAP antibody 44E5_15C5 to the IL1RAP-positive cell lines EOL1 and Karpas 299 was shown. The DMS79 cell line is IL1RAP-negative and showed a lack of binding to the IL1RAP antibody 44E5_15C5.
[0253] Figure 3 It is a diagram showing the competition class arrangement of antibodies.
[0254] Figure 4A 、 4B4C and 4D show that the anti-IL1RAP antibody binds to the IL1RAP ortholog. Figure 4A ), crab-eating macaque ( Figure 4B ), rat IL1RAP ( Figure 4C ) and mouse IL1RAP ( Figure 4D ) were evaluated for cell surface binding of anti-IL1RAP antibodies to 293 cells. 21H5 is a mouse antibody against human IL1RAP. CBIgG1 (anti-hen egg lysozyme antibody, CrownBio TM ) as a negative control.
[0255] Figure 5 The internalization of IL1RAP antibody 44E5_15C5 into EOL1 cells was shown. Live EOL1 cells were incubated with IL1RAP antibody 44E5_15C5 for 0.5 hours at 37° C. After centrifugation, the cells were fixed, permeabilized, and co-stained with LAMP1 antibody.
[0256] Figure 6 A, 6B and 6C show the expression of cytokines in the human leukemia cell line EOL1 ( Figure 6 A) and Karpas299( Figure 6 Internalization and in vitro efficacy of IL1RAP antibodies in B). No cytotoxicity in the IL1RAP negative cell line DMS79 ( Figure 6 C).
[0257] Figure 7 A, 7B, 7C, 7D, 7E and 7F show the expression of AML in the cell line EOL1 ( Figure 7 A), MOLM13( Figure 7 B)MOLM14( Figure 7 C), MV (4; 11) ( Figure 7 D), OCI / AML1( Figure 7 E) and KG-1( Figure 7 F) In vitro efficacy of anti-IL1RAP ADC. 3,000 cells were seeded in 96-well plates and treated with Tesirine PBD-conjugated antibodies for 5 days. TM Cells were lysed with ELISA kit (Promega) 2.0, and the results were recorded photometrically. Antibodies conjugated to hIgG1 (anti-HBV surface Ag antibody, produced in-house) were included as negative controls. IC50 values are listed at the bottom of each graph.
[0258] Figure 8A, 8B and 8C show the blockade of IL1α / β signaling by anti-IL1RAP antibodies. IL1RAP antibodies 37E10_15B5, 44E5_15C5, 16H2_17D2 and 36A10_21B6 showed potent inhibition of IL1R1 signaling in a dose-dependent manner ( Figure 8 A). Antibodies 37E10_15B5 and 44E5_15C5 were expressed at subnanomolar EC 50 Blocking IL-1β and IL-1α signaling ( Figure 8 B and 8C).
[0259] Figure 9 A and 9B show the blockade of IL-33 signaling by anti-IL1RAP antibodies. HEK-blue IL-33 cells (Invivogen, CA) were harvested and seeded in duplicate at a density of 50,000 cells per well in 96-well plates. Antibodies or corresponding human IgG1 control antibodies were added at serial dilutions starting at 10 μg / ml ( Figure 9 A) or concentrations of 1 and 10 μg / ml ( Figure 9 B) was added to the wells. After incubation of the antibody with the cells for 30 minutes, IL-33 was added to a final concentration of 0.5 ng / ml and the plates were incubated overnight. After 24 hours, substrate was added to the supernatant and the samples were analyzed based on absorbance at 620 nm. CBIgG1 (anti-hen egg lysozyme antibody, CrownBio TM ) as a negative control. DETAILED DESCRIPTION
[0260] Various aspects of the disclosure relate to anti-IL1RAP antibodies and antibody fragments, anti-IL1RAP ADCs and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for preparing such antibodies and fragments. Methods of using the antibodies and ADCs described herein to detect human IL1RAP, bind to and inhibit human IL1RAP on cells expressing IL1RAP, inhibit IL-1 (e.g., IL-1β and / or IL-1α signaling) in vivo and / or treat IL1RAP-related disorders (e.g., cancer, including but not limited to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), lung cancer, including non-small cell lung cancer (NSCLC), and ovarian cancer).
[0261] In one embodiment, the anti-IL1RAP antibody or ADC of the present invention is administered in combination with one or more immune checkpoint inhibitors (e.g., antibodies or small molecule immune checkpoint inhibitors) for the treatment of cancer. In another embodiment of the present invention, the anti-IL1RAP antibody drug conjugate (ADC) of the present invention (e.g., an IL1RAP antibody of the present invention conjugated to a toxin) internalizes and induces cell death of cells that endogenously express IL1RAP.
[0262] I. Definition
[0263] In order that the present invention may be more readily understood, certain terms are first defined. Additionally, it should be noted that whenever a value or range of values for a parameter is stated, values and ranges intermediate to the stated values are also intended to be part of the present invention.
[0264] The terms "interleukin 1 receptor accessory protein antibody" or "anti-IL1RAP antibody" are used interchangeably herein to refer to an antibody that specifically binds to IL1RAP, e.g., human IL1RAP. An antibody that "binds" an antigen of interest (i.e., IL1RAP) is one that is capable of binding to the antigen with sufficient affinity to allow the antibody to be used to target cells expressing the antigen. In a preferred embodiment, the antibody specifically binds to human IL1RAP (hIL1RAP). Examples of anti-IL1RAP antibodies are disclosed in the Examples below. Unless otherwise indicated, the term "anti-IL1RAP antibody" refers to an antibody that binds to wild-type IL1RAP, a variant, or an isoform of IL1RAP.
[0265] Several different isoforms of IL1RAP have been identified. An exemplary amino acid sequence of wild-type human IL1RAP is provided below in SEQ ID NO: 286, which contains 570 amino acids. The extracellular domain (ECD) of IL1-RAP contains amino acids 21-367 of SEQ ID NO: 286.
[0266]
[0267]
[0268] As used herein, the term "specific binding" or "specifically binds" refers to the interaction of an IL1RAP antibody or ADC with a second chemical substance, and refers to the interaction being dependent on the presence of a specific structure (e.g., an antigenic determinant or epitope) on the chemical substance; for example, the antibody recognizes and binds to a specific protein structure, rather than proteins in general. If the antibody or ADC is specific for epitope "A," then in a reaction containing labeled "A" and the antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of labeled A bound to the antibody or ADC.
[0269] In one embodiment, as used herein, the phrase "specifically binds to hIL1RAP" or "specifically binds to hIL1RAP" refers to an anti-IL1RAP antibody or ADC that binds to IL1RAP (human or cynomolgus monkey IL1RAP) at a specific affinity of about 2,000 nM or less, about 1,000 nM or less, about 500 nM or less, about 200 nM or less, about 100 nM or less, about 75 nM or less, about 25 nM or less, about 21 The dissociation constant (K) of the present invention may be about 1.5 nM or less, about 2.5 nM or less, about 1.2 nM or less, about 1.5 nM or less, about 2.5 nM or less, about 3.5 nM or less, about 4.5 nM or less, about 5.5 nM or less, about 6.5 nM or less, about 7.5 nM or less, about 8.5 nM or less, about 9.5 nM or less, about 10.5 nM or less, about 11.5 nM or less, about 10.5 nM or less, about 12.5 nM or less, about 11.5 nM or less, about 10.5 nM or less, about 9.5 nM or less, about 8.5 nM or less, about 7.5 nM or less, about 6.5 nM or less, about 5.5 nM or less, about 4.5 nM or less, about 3.5 nM or less, about 2.5 nM or less, about 1 nM or less, about 0.5 nM or less, about 0.3 nM or less, about 0.1 nM or less, about 0.01 nM or less, or about 0.001 nM or less. D In another embodiment, as used herein, the phrase "specifically binds to hIL1RAP" or "specifically binds to hIL1RAP" refers to an anti-IL1RAP antibody or ADC that binds to IL1RAP with a dissociation constant (K) of between about 1 pM (0.001 nM) and 2,000 nM, between about 500 pM (0.5 nM) and about 1,000 nM, between about 500 pM (0.5 nM) and 500 nM, between about 1 nM and 200 nM, between about 1 nM and 100 nM, between about 1 nM and 50 nM, between about 1 nM and 20 nM, or between about 1 nM and 5 nM. D ) ability to interact. In one embodiment, K D By surface plasmon resonance or by bio-layer interferometry or by any other method known in the art. Bio-layer interferometry refers to an optical phenomenon that allows the analysis of real-time biospecific interactions by measuring the interference pattern of reflected white light, for example using Octet TM System (ForteBio, Pall Corp. Fremont, CA). TM For further description of the system, see Li, B et al., (2011) J. Pharm. Biomed. Anal. 54(2): 286-294 and Abdiche, YN et al., (2009) Anal. Biochem. 386(2): 172-180, the contents of which are incorporated herein by reference.
[0270] The term "antibody" broadly refers to an immunoglobulin (Ig) molecule, typically composed of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivative thereof, which retains the essential target binding characteristics of an Ig molecule. Such mutant, variant, or derivative antibody forms are well known in the art. Non-limiting embodiments thereof are discussed below.
[0271] In a full-length antibody, each heavy chain consists of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is composed of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The immunoglobulin molecule can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) and class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2) or subclass.
[0272] As used herein, the term "antigen-binding portion" of an antibody (or simply "antibody portion") refers to a fragment of one or more antibodies that retains the ability to specifically bind to an antigen (e.g., hIL1RAP). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Such antibody embodiments can also be bispecific, dual-specific, or multispecific; specifically binding to two or more different antigens. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region; (iii) an Fd fragment, consisting of the VH and CH1 domains; (iv) an Fv fragment, consisting of the VL and VH domains of one arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546, Winter et al., PCT Publication WO 90 / 05144A1, incorporated herein by reference), which contains a single variable domain; and (vi) isolated complementarity determining regions (CDRs). Moreover, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods to form a single protein chain in which the VL and VH regions pair to form a monovalent molecule (referred to as single-chain Fv (scFv); see, e.g., Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single-chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. In certain embodiments, scFv molecules can be incorporated into fusion proteins. Other forms of single-chain antibodies, such as diabodies, are also encompassed. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain, but the linker used is too short to allow pairing between the two domains on the same chain, thereby forcing these domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger, P. et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, RJ et al. (1994) Structure 2: 1121-1123). Such antibody binding portions are well known in the art (Kontermann and Dubel, eds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5)).
[0273] As used herein, the term "antibody construct" refers to a polypeptide comprising one or more antigen-binding moieties disclosed herein that are connected to a linker polypeptide or an immunoglobulin constant domain. A linker polypeptide comprises two or more amino acid residues connected by a peptide bond and is used to connect one or more antigen-binding moieties. Such linker polypeptides are well known in the art (see, for example, Holliger, P. et al., (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, RJ et al., (1994) Structure 2: 1121-1123). An immunoglobulin constant domain refers to a heavy chain or light chain constant domain. Antibody portions (such as Fab and F (ab') 2 fragments) can be prepared by conventional techniques from whole antibodies, such as digesting intact antibodies with papain or pepsin, respectively. However, as described herein, antibodies, antibody portions, and immunoadhesion molecules can be obtained using standard recombinant DNA techniques.
[0274] As used herein, an "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds IL1 RAP is substantially free of antibodies that specifically bind antigens other than IL1 RAP). However, an isolated antibody that specifically binds IL1 RAP may have cross-reactivity with other antigens (e.g., IL1 RAP molecules from other species). Furthermore, an isolated antibody may be substantially free of other molecular species and / or chemical substances.
[0275] The term "humanized antibody" refers to an antibody comprising heavy and light chain variable region sequences from non-human species (e.g., mouse), but wherein at least a portion of the VH and / or VL sequence has been changed to a more "human-like" (i.e., more similar to a human germline variable sequence). In particular, the term "humanized antibody" is an antibody or a variant, derivative, analog, or fragment thereof that immunospecifically binds to an antigen of interest and comprises a framework region (FR) having a substantially human antibody amino acid sequence and a complementary determining region (CDR) having a substantially non-human antibody amino acid sequence. As used herein, the term "substantially" in the context of a CDR refers to a CDR that has at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical amino acid sequence to the amino acid sequence of a non-human antibody CDR. Humanized antibodies comprise substantially all of at least one and typically two variable domains (Fab, Fab', F(ab')2, FabC, Fv), wherein all or substantially all CDR regions correspond to those of non-human immunoglobulins (i.e., donor antibodies) and all or substantially all framework regions are those of human immunoglobulin consensus sequences. Preferably, the humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin. In some embodiments, the humanized antibody contains two light chains and at least the variable domains of a heavy chain. The antibody may also comprise the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, the humanized antibody contains only humanized light chains. In other embodiments, the humanized antibody contains only humanized heavy chains. In specific embodiments, the humanized antibody contains only humanized variable domains of light chains and / or humanized heavy chains.
[0276] Humanized antibodies can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including but not limited to IgG1, IgG2, IgG3, and IgG4. A humanized antibody may comprise sequences from more than one class or isotype, and specific constant domains may be selected to optimize desired effector functions using techniques well known in the art.
[0277] The terms "Kabat number," "Kabat definition," and "Kabat notation" are used interchangeably herein. These terms are well known in the art and refer to a system for numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody or antigen-binding portion thereof (Kabat et al., (1971) Ann. NY Acad, Sci. 190:382-391 and Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region of CDR1 ranges from amino acid positions 31 to 35, CDR2 from amino acid positions 50 to 65, and CDR3 from amino acid positions 95 to 102. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.
[0278] As used herein, the term "CDR" refers to the complementarity determining region within an antibody variable sequence. For each variable region, there are three CDRs in each variable region of the heavy chain (HC) and light chain (LC), designated CDR1, CDR2, and CDR3 (or specifically, HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3). As used herein, the term "CDR set" refers to a group of three CDRs that appear in a single variable region capable of binding an antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries that define the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and colleagues (Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987) and Chothia et al., Nature 342:877-883 (1989)) found that certain subportions within the Kabat CDRs adopt nearly identical peptide backbone conformations despite having great diversity at the amino acid sequence level. These subportions are referred to as L1, L2, and L3 or H1, H2, and H3, where "L" and "H" denote the light and heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have similarities to the Kabat CDRs. Boundaries of CDR overlap. Padlan (FASEB J. 9: 133-139 (1995)) and MacCallum (J Mol Biol 262 (5): 732-45 (1996)) have described other boundaries of CDR overlap using the Kabat CDR definition. Still other CDR boundary definitions may not strictly follow one of the above systems but still overlap with the Kabat CDRs, although they may be shortened or lengthened, but based on predictions or experimental results, specific residues or groups of residues, or even entire CDRs, will not significantly affect antigen binding. The methods used herein can utilize CDRs defined according to any of these systems, although preferred embodiments use CDRs defined according to Kabat or Chothia.
[0279] As used in this article, the term "framework" or "framework sequence" refers to the variable region minus the remaining sequence of CDR. Because the exact definition of CDR sequences can be determined by different systems, the implication of framework sequence should accordingly be explained differently. The six CDRs (CDR-L1, CDR-L2 and CDR-L3 of light chain and CDR-H1, CDR-H2 and CDR-H3 of heavy chain) are also divided into four subregions (FR1, FR2, FR3 and FR4) on each chain in the framework region on light chain and heavy chain, wherein CDR1 is between FR1 and FR2, and CDR2 is between FR2 and FR3 and CDR3 is between FR3 and FR4. When specific subregion is not designated as FR1, FR2, FR3 or FR4, framework region, as other refers to, represents the FR of combination in the variable region of single, naturally occurring immunoglobulin chain. As used in this article, FR represents one of four subregions, and FR represents two or more of the four subregions constituting framework region.
[0280] The framework region and CDR region of humanized antibody do not have to correspond exactly to the parent sequence, for example, can carry out mutagenesis donor antibody CDR or common framework by replacing, inserting and / or deleting at least one amino acid residue, so that the CDR or framework residues at this site do not correspond to the donor antibody or common framework. In a preferred embodiment, however, such mutation will not be widely present. Usually, at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% of the humanized antibody residues will correspond to those parent FR and CDR sequences. As used in this article, the term "common framework" refers to the framework region in the common immunoglobulin sequence. As used in this article, the term "common immunoglobulin sequence" refers to the sequence formed by the most frequently occurring amino acid (or nucleotide) in the relevant immunoglobulin sequence family (see, for example, Winnaker, From Genes to Clones Verlagsgesellschaft, Weinheim, Germany 1987). In the immunoglobulin family, each position in the common sequence is occupied by the most frequently occurring amino acid in the position in the family. If two amino acids occur equally, then any one can be included in the common sequence.
[0281] "Percent (%) amino acid sequence identity" for a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. For the purpose of determining percent amino acid sequence identity, alignment can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. In one embodiment, the present disclosure includes amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 190.
[0282] In one embodiment, the antibody or antigen binding portion thereof is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). In one embodiment, the antibody or antigen binding portion thereof is unable to induce ADCC.
[0283] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing complement dependent cytotoxicity (CDC).In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing CDC.
[0284] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing ADCC and CDC. In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing ADCC or CDC.
[0285] The term "multivalent antibody" is used herein to refer to an antibody comprising two or more antigen binding sites. In certain embodiments, a multivalent antibody can be engineered to have three or more antigen binding sites and is not typically a naturally occurring antibody.
[0286] The term "multispecific antibody" refers to an antibody that is capable of binding to two or more unrelated antigens.
[0287] As used interchangeably herein, the terms "dual variable domains" or "DVDs" are antigen binding proteins comprising two or more antigen binding sites, and are tetravalent or more valent binding proteins. Such DVDs can be monospecific (i.e., capable of binding to one antigen) or multispecific (i.e., capable of binding to two or more antigens). A DVD binding protein comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides is referred to as a DVD Ig. Each half of a DVD Ig comprises a heavy chain DVD polypeptide and a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs, which participate in antigen binding at each antigen binding site. In one embodiment, the CDRs described herein are used in anti-IL1RAP DVDs.
[0288] The term "activity" includes activities such as the binding specificity / affinity of an antibody or ADC (e.g., an anti-hIL1RAP antibody or ADC that binds to an IL1RAP antigen) for an antigen. In one embodiment, the activity of an anti-IL1RAP antibody or anti-IL1RAP ADC includes, but is not limited to, binding to IL1RAP in vitro; binding to IL1RAP on cells expressing IL1RAP in vitro; modulating (e.g., inhibiting) IL-1 (e.g., IL-1β and / or IL-1α) signaling; inducing cell death in cells expressing IL1RAP (including leukemia cells); inhibiting cancer cell invasion and metastasis; reducing or inhibiting cancers, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), lung cancer, including non-small cell lung cancer (NSCLC), and ovarian cancer; and reducing or inhibiting tumor cell proliferation or tumor growth in vivo. In one embodiment, the anti-IL1RAP antibody or ADC is capable of internalizing into cells expressing IL1RAP and / or inducing cytotoxicity.
[0289] In one embodiment, the antibody or antigen binding portion thereof is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). In one embodiment, the antibody or antigen binding portion thereof is unable to induce ADCC.
[0290] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing complement dependent cytotoxicity (CDC).In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing CDC.
[0291] In one embodiment, the antibody, or antigen binding portion thereof, is capable of inducing ADCC and CDC. In one embodiment, the antibody, or antigen binding portion thereof, is not capable of inducing ADCC and CDC.
[0292] The term "epitope" refers to the region of an antigen that is bound by an antibody, antibody fragment, or ADC. In certain embodiments, epitope determinants include chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural characteristics and / or specific charge characteristics. In certain embodiments, an antibody is said to specifically bind an antigen when it preferentially recognizes a target antigen in a complex mixture of proteins and / or macromolecules.
[0293] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that can be used to analyze real-time biospecific interactions by detecting changes in protein concentration in a biosensor matrix (e.g., using the BIAcore system) (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further description, see U. et al., (1993) Ann.Biol.Clin.51:19-26; U. et al. (1991) Biotechniques 11:620-627; Johnsson, B. et al. (1995) J. Mol. Recognit. 8:125-131; and Johnnson, B. et al. (1991) Anal. Biochem. 198:268-277.
[0294] As used herein, the term " on ” or “k a ” is intended to refer to the association rate constant for the binding of an antibody to an antigen to form an antibody / antigen complex.
[0295] As used herein, the term " off ” or “k d ” is intended to refer to the dissociation rate constant of the antibody from the antibody / antigen complex
[0296] As used herein, the term "K D ” is intended to refer to the equilibrium dissociation constant for a specific antibody-antigen interaction. K D By k a / k dIn one embodiment, an antibody of the invention has a K of about 2,000 nM or less, about 1,000 nM or less, about 500 nM or less, about 200 nM or less, about 100 nM or less, about 75 nM or less, about 25 nM or less, about 21 nM or less, about 12 nM or less, about 11 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 0.5 nM or less, about 0.3 nM or less, about 0.1 nM or less, about 0.01 nM or less, or about 0.001 nM or less. D .
[0297] As used herein, the term "competitive binding" refers to a situation where a first antibody competes with a second antibody for a binding site on a third molecule (eg, an antigen). In one embodiment, competitive binding between two antibodies is determined using FACS analysis.
[0298] The term "competitive binding assay" is an assay used to determine whether two or more antibodies bind to the same epitope. In one embodiment, the competitive binding assay is a competition fluorescence activated cell sorting (FACS) assay, which is used to determine whether two or more antibodies bind to the same epitope by determining whether the fluorescent signal of the labeled antibody is reduced due to the introduction of an unlabeled antibody, where competition for the same epitope will reduce the level of fluorescence.
[0299] As used herein, the term "labeled antibody" refers to an antibody or antigen-binding portion thereof that has a label incorporated therein to provide for identification of a binding protein (e.g., an antibody). Preferably, the label is a detectable marker, such as a polypeptide incorporating a radiolabeled amino acid or attached to a biotin moiety that can be detected by labeled avidin (containing a fluorescent marker or enzymatically active streptavidin that can be detected optically or colorimetrically). Examples of polypeptide labels include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H. 14 C. 35 S. 90 Y. 99 Tc, 111 In, 125 I. 131 I. 177 Lu, 166 Ho or 153Sm); fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzyme labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotin groups; predetermined polypeptide epitopes recognized by secondary reporter proteins (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic agents, such as gadolinium chelates.
[0300] The term "antibody drug conjugate" or "ADC" refers to a binding protein (such as an antibody or its antigen binding fragment) that is chemically linked to one or more chemicals (also referred to herein as medicaments), which may optionally be therapeutic agents or cytotoxic agents. In a preferred embodiment, the ADC comprises an antibody, a cytotoxic or therapeutic drug and a linker that can attach the drug to or be conjugated to the antibody. The ADC typically has 1 to 8 drugs conjugated to the antibody anywhere, including 2, 4, 6 or 8 drug-loaded substances. Non-limiting examples of drugs that may be included in the ADC are mitotic inhibitors, antitumor antibiotics, immunomodulators, carriers for gene therapy, alkylating agents, anti-angiogenic agents, antimetabolites, boron-containing agents, chemoprotectants, hormone agents, antihormonal agents, corticosteroids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, topoisomerase inhibitors, tyrosine kinase inhibitors, and radiosensitizers.
[0301] The terms "V-aggregate domain-containing T cell activation inhibitor 1 antibody drug conjugate," "anti-IL1RAP antibody drug conjugate," or "anti-IL1RAP ADC" are used interchangeably herein to refer to an ADC comprising an antibody that specifically binds to IL1RAP, wherein the antibody is conjugated to one or more chemical agents or payloads. In one embodiment, the chemical agent is linked to the antibody via a linker.
[0302] The term "drug to antibody ratio" or "DAR" refers to the amount of drug (e.g., IGN, auristatin, or maytansine alkaloid) attached to the antibody of an ADC. The DAR of an ADC can range from 1 to 8, although higher loadings (e.g., 10) are possible depending on the number of attachment sites on the antibody. The term DAR can be used with reference to the amount of drug loaded onto a single antibody, or can be used with reference to the average DAR or mean DAR of a group of ADCs.
[0303] As used herein, the term "condition associated with IL1RAP" includes any condition or disease (including proliferative conditions, such as cancer) that is marked, diagnosed, detected, or identified by a phenotypic or genotypic abnormality in the genetic components or expression of IL1RAP during the course or etiology of the disease or condition. In this regard, an abnormality or determinant of the IL1RAP phenotype may include, for example, an increase or decrease in the expression level of the IL1RAP protein in one cell population (e.g., a cancer cell population) compared to another cell population (e.g., a normal cell population), or an increase or decrease in the expression of the IL1RAP protein in certain definable cell populations, or an increase or decrease in the expression of the IL1RAP protein at an inappropriate time or stage in the cell life cycle. It will be appreciated that similar expression patterns of IL1RAP genotypic determinants (e.g., mRNA transcript levels) may also be used to classify or detect conditions associated with IL1RAP. In one embodiment, the condition associated with IL1RAP is a leukemia, such as acute myeloid leukemia (AML). In another embodiment, the condition associated with IL1RAP is myelodysplastic syndrome (MDS). In another embodiment, the condition associated with IL1RAP is lung cancer. In another embodiment, the condition associated with IL1RAP is non-small cell lung cancer (NSCLC). In another embodiment, the condition associated with IL1RAP is ovarian cancer.
[0304] As used herein, the term "cancer" refers to or describes a physiological condition in mammals characterized by uncontrolled cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include, but are not limited to, breast cancer (tubular A type, TNBC, duct), prostate cancer, squamous cell tumors, squamous cell carcinoma (e.g., squamous cell lung cancer or squamous cell head and neck cancer), neuroendocrine tumors, urothelial carcinoma, vulvar cancer, mesothelioma, liver cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, skin or intraocular malignant melanoma, kidney cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, anal region cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer , vaginal cancer, vulvar cancer, non-Hodgkin's lymphoma, esophageal cancer, small bowel cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system tumors (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, environmentally induced cancers, including those induced by asbestos, hematological malignancies including, for example, multiple myeloma, B-cell lymphoma, Hodgkin's Lymphoma / primary mediastinal B-cell lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), myeloproliferative disorders (MPD), chronic lymphoid leukemia, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, immunogenic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, mycosis fungoides, anaplastic large cell lymphoma, T-cell lymphoma, and precursor T-lymphoblastic lymphoma The present invention is also suitable for treating metastatic cancer.
[0305] In one embodiment, the antibodies or ADCs of the invention are administered to patients with solid tumors, including advanced solid tumors. In one embodiment, the antibodies or ADCs of the invention are administered to patients with leukemia. In another embodiment, administration of the antibodies or ADCs of the invention induces cell death in cells expressing IL1RAP.
[0306] As used herein, the term "IL1RAP-expressing tumor" refers to a tumor that expresses the IL1RAP protein (including tumors containing tumor-infiltrating cells that express the IL1RAP protein). In one embodiment, IL1RAP expression in a tumor is determined using immunohistochemical staining of tumor cell membranes, wherein any immunohistochemical staining above background levels in a tumor sample indicates that the tumor is an IL1RAP-expressing tumor. In another embodiment, an IL1RAP-expressing tumor is identified in a patient when greater than 1%, greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90% or more of the cells in the tumor sample are positive for IL1RAP expression. In another embodiment, positive IL1RAP expression is determined based on membrane staining, as determined by, for example, immunohistochemical (IHC) analysis.
[0307] A tumor expressing IL1RAP is identified as having "elevated levels of IL1RAP" or "expressing IL1RAP at elevated levels" when the level of IL1RAP is higher than the level in tissue surrounding the cancer. In some embodiments, "elevated levels of IL1RAP" are where 5% or more of the cells in a tumor sample have membrane staining. In some embodiments, "high levels" for IL1RAP are 5% or more staining, for example, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of the cells in a tumor sample are stained. In some embodiments, protein expression levels can be measured by IHC analysis.
[0308] A tumor expressing IL1RAP is identified as having "reduced levels of IL1RAP" or "expressing IL1RAP at reduced levels" when 5% or fewer of the cells in a tumor sample have membrane staining. In some embodiments, "low levels" of IL1RAP are 5% or less staining, for example, 4.9, 4.5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1% or fewer of the cells in a tumor sample are stained. In some embodiments, protein expression levels can be measured by IHC analysis.
[0309] Cells that do not express IL1RAP can also be described as expressing "low levels of IL1RAP." Thus, the phrase "expressing low levels of IL1RAP" encompasses not expressing IL1RAP. In some embodiments, low levels of IL1RAP are within background staining levels. In some embodiments, a sample that is "negative" for IL1RAP has no or low levels of IL1RAP expression. In some embodiments, staining for IL1RAP is negative when no, less than 5%, 4%, 3%, 2%, or 1% of cells have membrane staining for IL1RAP.
[0310] As used herein, the term "tumor sample" refers to a tumor tissue or cell sample obtained from a solid tumor. The sample may include both tumor cells and tumor-infiltrating cells, such as tumor-infiltrating immune cells.
[0311] As used herein, the term "non-cancerous sample" or "normal sample" refers to a sample from a normal tissue (e.g., a lung or ovarian tissue sample or a normal cell sample). In some embodiments, the non-cancerous sample is from the same subject, but from a different part of the subject being tested. In some embodiments, the non-cancerous sample is from a tissue area surrounding or adjacent to the cancer. In some embodiments, the non-cancerous sample is not from the subject being tested, but is a sample from a subject known to have or not have the disease (e.g., a specific cancer, such as an IL1RAP-related disorder). In some embodiments, the non-cancerous sample is from the same subject, but from a time point before the subject develops cancer. In some embodiments, the reference sample is a benign cancer sample (e.g., a benign ovarian cancer sample) from the same or different subject.
[0312] Methods for detecting IL1RAP expression in tumors are well known in the art.
[0313] The terms "overexpress," "overexpression," or "overexpressed" are used interchangeably to refer to a gene that is transcribed or translated at a detectably higher level, typically in cancer cells, compared to normal cells. Thus, overexpression refers to overexpression of protein and RNA (due to increased transcription, post-transcriptional processing, translation, post-translational processing, altered stability, and altered protein degradation), as well as localized overexpression due to altered protein trafficking (increased nuclear localization) and enhanced functional activity (e.g., in the case of increased enzymatic hydrolysis of substrates). Thus, overexpression refers to protein or RNA levels. Overexpression can also be 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to normal or comparison cells. In certain embodiments, anti-IL1RAP antibodies or ADCs are used to treat solid tumors in which IL1RAP may be overexpressed.
[0314] As used herein, the term "administer" refers to the delivery of a substance (e.g., an anti-IL1RAP antibody or ADC) to achieve a therapeutic purpose (e.g., treating an IL1RAP-related disorder or inhibiting or reducing a tumor). The mode of administration can be parenteral, enteral, and topical. Parenteral administration is typically performed by injection and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0315] As used herein, the term "combination therapy" refers to the administration of two or more therapeutic substances (e.g., anti-IL1RAP antibodies or ADCs) and additional therapeutic agents. The additional therapeutic agent may be administered simultaneously with, before, or after the administration of the anti-IL1RAP antibody or ADC. In one embodiment, the anti-IL1RAP antibody or ADC of the present invention is administered in combination with one or more immune checkpoint inhibitors (e.g., one or more antibodies or small molecule immune checkpoint inhibitors) for the treatment of cancer.
[0316] As used herein, the term "effective amount" or "therapeutically effective amount" refers to the amount of a drug (e.g., an antibody or ADC) that is sufficient to alleviate or improve the severity and / or duration of a condition (e.g., cancer) or one or more of its symptoms, to prevent the progression of the condition, to cause condition inhibition, to prevent the recurrence, development, onset or progression of one or more symptoms associated with the condition, to detect the condition, or to enhance or improve the preventive or therapeutic effects of another therapy (e.g., a prophylactic or therapeutic agent). An effective amount of an antibody or ADC can, for example, inhibit tumor growth (e.g., inhibit tumor volume increase), reduce tumor growth (e.g., reduce tumor volume), reduce the number of cancer cells and / or alleviate one or more symptoms associated with cancer to some extent. An effective amount can, for example, improve disease-free survival (DFS), improve overall survival (OS) or reduce the likelihood of recurrence.
[0317] Various aspects of the invention are described in more detail in the following subsections.
[0318] III. Anti-IL1RAP Antibodies
[0319] One aspect disclosed herein provides a humanized anti-IL1RAP antibody or an antigen-binding portion thereof. Another aspect disclosed herein provides a human anti-IL1RAP antibody or an antigen-binding portion thereof. In one embodiment, the antibodies disclosed herein bind to human IL1RAP. In another embodiment, the antibodies disclosed herein bind to cynomolgus monkey IL1RAP. In another embodiment, the antibodies disclosed herein bind to human IL1RAP expressed on tumor cells.
[0320] Another aspect disclosed herein relates to an antibody drug conjugate (ADC) comprising an anti-IL1RAP antibody as described herein and at least one drug. The antibodies or ADCs disclosed herein have features including, but not limited to, binding to human IL1RAP in vitro, regulating (e.g., inhibiting) IL-1 signaling, inducing cell death in cells expressing IL1RAP (including but not limited to leukemia cells), and reducing or inhibiting cancer cells, tumor cell proliferation or tumor growth or tumor invasion or metastasis. In particular, the ADCs disclosed herein have features including, but not limited to, inducing cell death in cells expressing IL1RAP, such as leukemia cells expressing IL1RAP. In one embodiment, the anti-IL1RAP antibodies or ADCs disclosed herein are capable of internalizing into cells expressing IL1RAP.
[0321] In one embodiment, as described in the examples below, anti-IL1RAP antibodies having the ability to bind to IL1RAP are disclosed. The novel antibodies are collectively referred to herein as "IL1RAP antibodies." The anti-IL1RAP antibodies, ADCs, or antigen-binding fragments thereof are capable of inhibiting or reducing tumor growth in vivo. The tumor can be an IL1RAP-negative tumor or a tumor that expresses IL1RAP. In various embodiments, the anti-IL1RAP antibodies, ADCs, or antigen-binding fragments thereof are capable of modulating the biological function of IL1RAP. In other embodiments of the foregoing aspects, the anti-IL1RAP antibodies, ADCs, or antigen-binding fragments thereof bind to IL1RAP on cells that express IL1RAP. Thus, the present disclosure includes anti-IL1RAP antibodies, ADCs, or antigen-binding portions thereof that are effective in inhibiting or reducing tumor growth. Without wishing to be bound by any particular theory, in one embodiment, anti-IL1RAP antibodies, antigen-binding portions thereof, and ADCs are capable of inhibiting multiple IL1RAP activities, including but not limited to IL-1β signaling through IL1RAP; IL-1α, IL-1β, and IL-38 signaling through IL-1R; IL-33 signaling through IL-33R; and IL-36Rα, IL-36β, and IL-36γ signaling through IL-36R. It is well known in the art that blocking IL-1β signaling is effective for treating lung cancer (see, e.g., Ridker et al., Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, New England J. Med., 2017; and Ridker et al., The Lancet, 390:1833-1842, 2017, the entire contents of each of which are expressly incorporated herein by reference). Thus, in one embodiment, the anti-IL1RAP antibodies, antigen-binding portions thereof, and ADCs described herein can be used to inhibit the downstream IL-1β pathway to treat cancer, such as lung cancer.
[0322] In addition, the inventors have further discovered that IL1RAP is expressed by leukemia cells (see Example 1). Therefore, anti-IL1RAP antibodies, ADCs, and antigen-binding portions thereof can be used to treat leukemias, such as acute myeloid leukemia, in a subject. Anti-IL1RAP antibodies, ADCs, and antigen-binding portions thereof can be used to treat myeloid disorders, such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), ovarian cancer, lung cancer, and non-small cell lung cancer. In one embodiment, greater than 1%, greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, or more cells in a leukemia sample are positive for IL1RAP expression. In another embodiment, the leukemia or tumor sample has a high level of IL1RAP expression. For example, in one embodiment, at least 5% or more of the cells in a leukemia or tumor sample have membrane staining. In another embodiment, a tumor sample obtained from a subject shows low levels of IL1RAP expression. The expression level of IL1RAP can be determined by any method known in the art. For example, the expression level of IL1RAP can be determined by immunohistochemical analysis. In another embodiment, the cancer has been previously treated with another anticancer agent or anticancer therapy (e.g., chemotherapy). In one embodiment, the cancer is resistant to chemotherapy.
[0323] Antibodies having any combination of the foregoing features are considered aspects of the present disclosure.ADCs, described in more detail below, may also have any of the foregoing features.
[0324] One aspect of the present disclosure relates to an anti-IL1RAP (anti-hIL1RAP) antibody drug conjugate (ADC) comprising an anti-hIL1RAP antibody conjugated to a drug via a linker. Exemplary anti-IL1RAP antibodies (and sequences thereof) that can be used in the ADC are as described herein.
[0325] The anti-IL1RAP antibodies described herein provide ADCs with the ability to bind to IL1RAP, so that cytotoxic molecules attached to the antibodies can be delivered to cells expressing IL1RAP, particularly cancer cells expressing IL1RAP.
[0326] Although the term "antibody" is used throughout, it is important to note that antibody fragments (i.e., antigen-binding portions of anti-IL1RAP) are also encompassed by the present disclosure and can be included in the embodiments (methods and compositions) described herein. For example, as described herein, anti-IL1RAP antibody fragments can be conjugated to a drug. In certain embodiments, the anti-IL1RAP antibody binding portion is a Fab, Fab', F(ab')2, Fv, disulfide-linked Fv, single domain antibody, or diabody.
[0327] Example 2 describes the generation of fully human IL1RAP antibodies against the extracellular domain of human IL1RAP. The amino acid sequences of the heavy and light chain variable regions of these human antibodies are shown in Table 5. The nucleotide sequences of the heavy and light chain variable regions of these human antibodies are shown in Table 6.
[0328] Thus, in one embodiment, the present disclosure includes a human anti-IL1RAP antibody, or antigen-binding portion thereof, comprising a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 9, 17, 25, 32, 40, 48, 56, 64, 71, 74, 83, 90, 96, 100, 106, 109, 116, 118, 121, 123, 125, 127, 130, 136, 140, 144, 151, 158, 163, 170, 173, 180, and 185, and a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: From the following amino acid sequences: 5, 13, 21, 29, 36, 44, 52, 60, 68, 73, 78, 82, 87, 93, 98, 103, 108, 113, 114, 120, 122, 124, 126, 128, 134, 137, 143, 147, 154, 160, 167, 172, 177, 184 and 189.
[0329] In one embodiment, the disclosure includes a human anti-IL1RAP antibody, or antigen-binding portion thereof, comprising a set of HC CDRs (CDR1, CDR2, and CDR3) selected from those shown in Table 5; and a set of LC CDRs (CDR1, CDR2, and CDR3) selected from those shown in Table 5.
[0330] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 5G8_18A1. The 5G8_18A1 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 4, a CDR2 domain having the amino acid sequence of SEQ ID NO: 3, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 2, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 8, a CDR2 domain having the amino acid sequence of SEQ ID NO: 7, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 6. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region having the amino acid sequence of SEQ ID NO: 5.
[0331] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 1, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 5, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
[0332] In one embodiment, the present disclosure relates to an anti-IL1RAP antibody, or an antigen-binding portion thereof, which is the human antibody 10C8_15A1. The 10C8_15A1 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 12, a CDR2 domain having the amino acid sequence of SEQ ID NO: 11, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 16, a CDR2 domain having the amino acid sequence of SEQ ID NO: 15, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 14. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 9 and a light chain variable region having the amino acid sequence of SEQ ID NO: 13.
[0333] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:9, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:9, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:13, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:13.
[0334] In one embodiment, the present disclosure relates to an anti-IL1RAP antibody, or an antigen-binding portion thereof, which is the human antibody 12F3_17C2. The 12F3_17C2 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 20, a CDR2 domain having the amino acid sequence of SEQ ID NO: 19, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 18, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 24, a CDR2 domain having the amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 22. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 17 and a light chain variable region having the amino acid sequence of SEQ ID NO: 21.
[0335] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 17, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 17, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 21, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 21.
[0336] In one embodiment, the present disclosure relates to an anti-IL1RAP antibody, or an antigen-binding portion thereof, which is the human antibody 16H2_17D2. The 16H2_17D2 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 28, a CDR2 domain having the amino acid sequence of SEQ ID NO: 27, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 32, a CDR2 domain having the amino acid sequence of SEQ ID NO: 23, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 31. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 25 and a light chain variable region having the amino acid sequence of SEQ ID NO: 29.
[0337] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:25, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:25, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:29, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:29.
[0338] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 32C12_21A4. The 32C12_21A4 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 32 and a light chain variable region having the amino acid sequence of SEQ ID NO: 36.
[0339] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:32, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:32, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:36, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:36.
[0340] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 34C11_21B2. The 34C11_21B2 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 41, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 47, a CDR2 domain having an amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 45. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 40 and a light chain variable region having an amino acid sequence of SEQ ID NO: 44.
[0341] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:40, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:40, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:44, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:44.
[0342] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 36A10_21B6. The 36A10_21B6 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 51, a CDR2 domain having an amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 55, a CDR2 domain having an amino acid sequence of SEQ ID NO: 54, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 53. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 48 and a light chain variable region having an amino acid sequence of SEQ ID NO: 52.
[0343] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:48, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:48, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:52, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:52.
[0344] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 39G1_21C4. The 39G1_21C4 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 59, a CDR2 domain having an amino acid sequence of SEQ ID NO: 58, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 57, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 63, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 61. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 56 and a light chain variable region having an amino acid sequence of SEQ ID NO: 60.
[0345] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:56, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:56, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:60, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:60.
[0346] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 37E10_15B5. The 37E10_15B5 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 64 and a light chain variable region having an amino acid sequence of SEQ ID NO: 68.
[0347] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:64, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:64, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:68, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:68.
[0348] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 44E5_15C5. The 44E5_15C5 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 72, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 65, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 71 and a light chain variable region having the amino acid sequence of SEQ ID NO: 73.
[0349] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:71, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:71, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:73, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:73.
[0350] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 38E10_21C3. The 38E10_21C3 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 77, a CDR2 domain having an amino acid sequence of SEQ ID NO: 76, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 75, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 81, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 74 and a light chain variable region having an amino acid sequence of SEQ ID NO: 78.
[0351] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:74, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:74, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:78, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:78.
[0352] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 10C8_C43A. The 10C8_C43A antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 12, a CDR2 domain having an amino acid sequence of SEQ ID NO: 11, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 16, a CDR2 domain having an amino acid sequence of SEQ ID NO: 15, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 14. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 9 and a light chain variable region having an amino acid sequence of SEQ ID NO: 82.
[0353] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:9, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:9, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:82, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:82.
[0354] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 16H2_17D1. The 16H2_17D1 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 86, a CDR2 domain having an amino acid sequence of SEQ ID NO: 85, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 89, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 88. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 83 and a light chain variable region having an amino acid sequence of SEQ ID NO: 87.
[0355] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:83, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:83, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:87, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:87.
[0356] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 24G3_17C5. The 24G3_17C5 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 92, a CDR2 domain having the amino acid sequence of SEQ ID NO: 91, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 95, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 94. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 90 and a light chain variable region having the amino acid sequence of SEQ ID NO: 93.
[0357] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:90, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:90, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:93, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:93.
[0358] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 26C5_15B4. The 26C5_15B4 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 92, a CDR2 domain having the amino acid sequence of SEQ ID NO: 97, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 99, a CDR2 domain having the amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 79. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 96 and a light chain variable region having the amino acid sequence of SEQ ID NO: 98.
[0359] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:96, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:96, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:98, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:98.
[0360] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 17E9_15B1. The 17E9_15B1 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 20, a CDR2 domain having the amino acid sequence of SEQ ID NO: 102, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 24, a CDR2 domain having the amino acid sequence of SEQ ID NO: 105, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 104. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 100 and a light chain variable region having the amino acid sequence of SEQ ID NO: 103.
[0361] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 100, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 100, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 103, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 103.
[0362] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 10C8_15A4. The 10C8_15A4 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 86, a CDR2 domain having an amino acid sequence of SEQ ID NO: 107, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 84, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 89, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 88. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 106 and a light chain variable region having an amino acid sequence of SEQ ID NO: 108.
[0363] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 106, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 106, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 108, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 108.
[0364] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 32A2_21A3. The 32A2_21A3 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 112, a CDR2 domain having the amino acid sequence of SEQ ID NO: 111, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 110, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 109 and a light chain variable region having the amino acid sequence of SEQ ID NO: 113.
[0365] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 109, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 109, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 113, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 113.
[0366] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 32C12_N26S. The 32C12_N26S antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 35, a CDR2 domain having an amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 33, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 39, a CDR2 domain having an amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 115. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 32 and a light chain variable region having an amino acid sequence of SEQ ID NO: 114.
[0367] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:32, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:32, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:114, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:114.
[0368] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 41G4_15B6. The 41G4_15B6 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 35, a CDR2 domain having the amino acid sequence of SEQ ID NO: 34, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 117, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 39, a CDR2 domain having the amino acid sequence of SEQ ID NO: 38, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 37. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 116 and a light chain variable region having the amino acid sequence of SEQ ID NO: 36.
[0369] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 116, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 116, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 36, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 36.
[0370] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 31F9_21A1. The 31F9_21A1 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 119, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 118 and a light chain variable region having the amino acid sequence of SEQ ID NO: 120.
[0371] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 118, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 118, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 120, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 120.
[0372] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 32D4_21D6. The 32D4_21D6 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 121 and a light chain variable region having an amino acid sequence of SEQ ID NO: 122.
[0373] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 121, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 121, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 122, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 122.
[0374] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 32F9_21A5. The 32F9_21A5 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 67, a CDR2 domain having an amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 70, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 69. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 123 and a light chain variable region having an amino acid sequence of SEQ ID NO: 124.
[0375] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 123, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 123, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 124, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 124.
[0376] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 33E9_21A5. The 33E9_21A5 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 26, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 125 and a light chain variable region having the amino acid sequence of SEQ ID NO: 126.
[0377] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 125, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 125, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 126, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 126.
[0378] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 35D11_22A1. The 35D11_22A1 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 67, a CDR2 domain having the amino acid sequence of SEQ ID NO: 66, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 101, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 129, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 69. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 127 and a light chain variable region having the amino acid sequence of SEQ ID NO: 128.
[0379] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 127, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 127, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 128, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 128.
[0380] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 39A9_28A4. The 39A9_28A4 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 133, a CDR2 domain having the amino acid sequence of SEQ ID NO: 132, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 131, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 70, a CDR2 domain having the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 135. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 130 and a light chain variable region having the amino acid sequence of SEQ ID NO: 134.
[0381] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 130, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 130, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 134, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 134.
[0382] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 34D1_21B3. The 34D1_21B3 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 51, a CDR2 domain having the amino acid sequence of SEQ ID NO: 50, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 49, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 55, a CDR2 domain having the amino acid sequence of SEQ ID NO: 139, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 138. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 136 and a light chain variable region having the amino acid sequence of SEQ ID NO: 137.
[0383] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 136, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 136, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 137, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 137.
[0384] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 33H2_21B1. The 33H2_21B1 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 142, a CDR2 domain having an amino acid sequence of SEQ ID NO: 42, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 141, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 47, a CDR2 domain having an amino acid sequence of SEQ ID NO: 46, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 45. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 140 and a light chain variable region having an amino acid sequence of SEQ ID NO: 143.
[0385] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 140, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 140, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 143, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 143.
[0386] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 36A12_21C1. The 36A12_21C1 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 146, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 150, a CDR2 domain having an amino acid sequence of SEQ ID NO: 149, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 148. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 144 and a light chain variable region having an amino acid sequence of SEQ ID NO: 147.
[0387] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 144, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 144, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 147, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 147.
[0388] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 38G11_28A2. The 38G11_28A2 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 43, a CDR2 domain having an amino acid sequence of SEQ ID NO: 153, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 152, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 157, a CDR2 domain having an amino acid sequence of SEQ ID NO: 156, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 151 and a light chain variable region having an amino acid sequence of SEQ ID NO: 154.
[0389] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 151, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 154, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154.
[0390] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 40C3_22B6. The 40C3_22B6 antibody comprises a heavy chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 43, a CDR2 domain having the amino acid sequence of SEQ ID NO: 159, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 145, and a light chain variable region comprising a CDR3 domain having the amino acid sequence of SEQ ID NO: 162, a CDR2 domain having the amino acid sequence of SEQ ID NO: 161, and a CDR1 domain having the amino acid sequence of SEQ ID NO: 148. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 158 and a light chain variable region having the amino acid sequence of SEQ ID NO: 160.
[0391] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 158, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 158, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 160, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 160.
[0392] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 5D12_18A4. The 5D12_18A4 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 166, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 163 and a light chain variable region having an amino acid sequence of SEQ ID NO: 167.
[0393] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 163, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 167, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167.
[0394] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 5D12_C108Y. The 5D12_C108Y antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 171, a CDR2 domain having an amino acid sequence of SEQ ID NO: 165, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 164, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 169, a CDR2 domain having an amino acid sequence of SEQ ID NO: 168, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 155. In a further embodiment, the present application discloses an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 170 and a light chain variable region having an amino acid sequence of SEQ ID NO: 172.
[0395] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 170, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 172, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172.
[0396] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 37D11_21C2. The 37D11_21C2 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 176, a CDR2 domain having an amino acid sequence of SEQ ID NO: 175, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 174, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 179, a CDR2 domain having an amino acid sequence of SEQ ID NO: 178, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 173 and a light chain variable region having an amino acid sequence of SEQ ID NO: 177.
[0397] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 173, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 173, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 177, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 177.
[0398] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 42D10_28A5. The 42D10_28A5 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 183, a CDR2 domain having an amino acid sequence of SEQ ID NO: 182, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 181, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 179, a CDR2 domain having an amino acid sequence of SEQ ID NO: 80, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 79. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 180 and a light chain variable region having an amino acid sequence of SEQ ID NO: 184.
[0399] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 180, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 180, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO: 184, or a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 184.
[0400] In one embodiment, the anti-IL1RAP antibody or antigen-binding portion thereof is the human antibody 34H8_21B4. The 34H8_21B4 antibody comprises a heavy chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 188, a CDR2 domain having an amino acid sequence of SEQ ID NO: 187, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 186, and a light chain variable region comprising a CDR3 domain having an amino acid sequence of SEQ ID NO: 63, a CDR2 domain having an amino acid sequence of SEQ ID NO: 62, and a CDR1 domain having an amino acid sequence of SEQ ID NO: 190. In a further embodiment, disclosed herein is an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 185 and a light chain variable region having an amino acid sequence of SEQ ID NO: 189.
[0401] In some embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:71, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:71, and / or a light chain having an amino acid sequence as set forth in SEQ ID NO:73, or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:73.
[0402] The foregoing anti-IL1RAP antibody CDR sequences establish a new family of IL1RAP binding proteins isolated according to the present disclosure and include antigen-binding polypeptides comprising the CDR sequences listed in Table 5 and in the sequence summary.
[0403] To generate and select CDRs with preferred IL1RAP binding and / or neutralization activity against hIL1RAP, standard methods known in the art for generating antibodies or antigen-binding portions, and evaluating the IL1RAP binding and / or neutralization characteristics of those antibodies or antigen-binding portions thereof, can be used, including but not limited to those specifically described herein.
[0404] In certain embodiments, the antibody comprises a heavy chain constant region, such as an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region. In certain embodiments, the anti-IL1RAP antibody, or its antigen-binding portion, comprises a heavy chain immunoglobulin constant domain selected from the group consisting of a human IgG constant domain, a human IgM constant domain, a human IgE constant domain, and a human IgA constant domain. In further embodiments, the antibody, or its antigen-binding portion, comprises an IgG1 heavy chain constant region, an IgG2 heavy chain constant region, an IgG3 constant region, or an IgG4 heavy chain constant region. Preferably, the heavy chain constant region is an IgG1 heavy chain constant region or an IgG4 heavy chain constant region. In one embodiment, the antibody, or its antigen-binding portion, is of the IgG4 isotype.
[0405] Furthermore, the antibody may comprise a light chain constant region, a kappa light chain constant region or a lambda light chain constant region. Preferably, the antibody comprises a kappa light chain constant region. Alternatively, the antibody portion may be, for example, a Fab fragment or a single-chain Fv fragment.
[0406] In certain embodiments, the anti-IL1RAP antibody binding portion is a Fab, Fab', F(ab')2, Fv, disulfide-linked Fv, scFv, single domain antibody, or diabody.
[0407] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, is a multispecific antibody, such as a bispecific antibody.
[0408] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:1 and / or a light chain constant region having the amino acid sequence set forth in SEQ ID NO:5.
[0409] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:9 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:13.
[0410] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 17 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 21.
[0411] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:25 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:29.
[0412] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:32 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:36.
[0413] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:40 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:44.
[0414] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:48 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:52.
[0415] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:56 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:60.
[0416] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:64 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:68.
[0417] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:71 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:73.
[0418] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:74 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:78.
[0419] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:9 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:82.
[0420] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:83 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:87.
[0421] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:90 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:93.
[0422] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:96 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:98.
[0423] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 100 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 103.
[0424] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:106 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:108.
[0425] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:109 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:113.
[0426] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO:32 and / or a light chain constant region having the amino acid sequence of SEQ ID NO:114.
[0427] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 116 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 36.
[0428] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 118 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 120.
[0429] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 121 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 122.
[0430] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 123 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 124.
[0431] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 125 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 126.
[0432] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 127 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 128.
[0433] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 130 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 134.
[0434] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 136 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 137.
[0435] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 140 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 143.
[0436] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 144 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 147.
[0437] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 151 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 154.
[0438] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 158 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 160.
[0439] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 163 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 167.
[0440] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 170 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 172.
[0441] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 173 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 177.
[0442] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 180 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 184.
[0443] In certain embodiments, the anti-IL1RAP antibody, or antigen-binding portion thereof, comprises a heavy chain constant region having the amino acid sequence of SEQ ID NO: 185 and / or a light chain constant region having the amino acid sequence of SEQ ID NO: 189.
[0444] It has been described that the amino acid residues in the replacement Fc portion are to change the antibody effector function (Winter et al., U.S. Patent Nos. 5,648,260 and 5,624,821, incorporated herein by reference). The Fc portion of an antibody mediates several important effector functions, such as cytokine induction, ADCC, phagocytosis, complement dependent cytotoxicity (CDC) and the half-life / clearance rate of antibodies and antigen-antibody complexes. In some cases, these effector functions are ideal for therapeutic antibodies, but in other cases, depending on the therapeutic purpose, may be unnecessary or even harmful. Certain human IgG isotypes (particularly IgG1 and IgG3) mediate ADCC and CDC by binding to FcγR and complement C1q, respectively. Neonatal Fc receptor (FcRn) is a key component that determines the circulating half-life of an antibody. In another embodiment, at least one amino acid residue in an antibody constant region (e.g., an antibody Fc region) is replaced so that the effector function of the antibody is changed.
[0445] One embodiment includes a labeled anti-IL1RAP antibody or antibody portion thereof, wherein the antibody is derivatized or linked to one or more functional molecules (e.g., another peptide or protein). For example, the labeled antibody can be derived from functionally linking an antibody or antibody portion of the present disclosure to one or more other molecular entities (by chemical coupling, genetic fusion, non-covalent association, or other means), such as another antibody (e.g., a bispecific antibody or diabody), a detection reagent, a pharmaceutical agent, a protein or peptide capable of mediating binding of the antibody or antibody portion to another molecule (e.g., a streptavidin core region or a polyhistidine tag), and / or a cytotoxic or therapeutic agent selected from the following: a mitotic inhibitor, an anti-tumor antibiotic, an immunomodulator, a vector for gene therapy, an alkylating agent, an anti-angiogenic agent, an antimetabolite, a boron-containing agent, a chemoprotectant, a hormonal agent, an anti-hormonal agent, a corticosteroid, a photoactive therapeutic agent, an oligonucleotide, a radionuclide agent, a topoisomerase inhibitor, a tyrosine kinase inhibitor, a radiosensitizer, and combinations thereof.
[0446] Useful detectable agents that can be derivatized with antibodies or their antibody moieties include fluorescent compounds. Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-naphthalenesulfonyl chloride, phycoerythrin, etc. Detectable enzymes can also be used to derivatize antibodies, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase, etc. When using a detectable enzyme to derivatize antibodies, the antibodies are detected by adding additional reagents, and the enzyme is used to produce a detectable reaction product. For example, when there is a detectable reagent horseradish peroxidase, adding hydrogen peroxide and diaminobenzidine generates a detectable colored reaction product. Antibodies can also be derivatized with biotin and detected by indirectly measuring the binding of avidin or streptavidin.
[0447] In one embodiment, the antibody is conjugated to an imaging agent. Examples of imaging agents that can be used in the compositions and methods described herein include, but are not limited to, radiolabels (e.g., indium), enzymes, fluorescent labels, luminescent labels, bioluminescent labels, magnetic labels, and biotin.
[0448] In one embodiment, the antibody or ADC is linked to a radiolabel, such as but not limited to indium ( 111 In). 111 Indium can be used to label the antibodies and ADCs described herein for use in identifying IL1RAP positive tumors. 111 I. The anti-IL1RAP antibodies (or ADCs) described herein are labeled with a bifunctional chelate, which is a bifunctional cyclohexyldiethylenetriaminepentaacetic acid (DTPA) chelate (see U.S. Pat. Nos. 5,124,471; 5,434,287; and 5,286,850, each of which is incorporated herein by reference).
[0449] Another embodiment of the present disclosure provides a glycosylated binding protein, wherein the anti-IL1RAP antibody or its antigen-binding portion comprises one or more carbohydrate residues. Nascent in vivo protein production may undergo further processing, known as post-translational modification. In particular, sugar (glycosyl) residues may be enzymatically added, a process known as glycosylation. The resulting protein with covalently attached oligosaccharide side chains is called a glycosylated protein or glycoprotein. Antibodies are glycoproteins that have one or more carbohydrate residues in the Fc domain and the variable domain. The carbohydrate residues in the Fc domain have an important influence on the effector function of the Fc domain and have minimal effect on antigen binding or the half-life of the antibody (R. Jefferis, Biotechnol. Prog. 21 (2005), pp. 11–16). Conversely, glycosylation of the variable domain may have an impact on the antigen binding activity of the antibody. Glycosylation in the variable domain can negatively affect antibody binding affinity, possibly due to steric hindrance (Co, MS et al., Mol. Immunol. (1993) 30: 1361-1367), or lead to increased affinity for the antigen (Wallick, SC et al., Exp. Med. (1988) 168: 1099-1109; Wright, A. et al., EMBO J. (1991) 10: 2717-2723).
[0450] One aspect of the present disclosure relates to the generation of glycosylation site mutations, wherein the O- or N-linked glycosylation site of a binding protein has been mutated. Such mutations can be generated using standard, well-known techniques by those skilled in the art. Glycosylation site mutations that retain biological activity but have increased or decreased binding activity are another object of the present disclosure.
[0451] In another embodiment, the glycosylation of the anti-IL1RAP antibody or antigen-binding portion is modified. For example, an aglycosylated antibody can be prepared (i.e., the antibody lacks glycosylation). For example, glycosylation can be altered to increase the affinity of the antibody for the antigen. Such carbohydrate modifications can be achieved, for example, by changing one or more sites in the antibody sequence. For example, one or more amino acid substitutions can be made to eliminate one or more variable region glycosylation sites, thereby eliminating glycosylation at that site. Such aglycosylation can increase the affinity of the antibody for the antigen. Such methods are further described in detail in PCT Publication WO2003016466A2 and U.S. Patent Nos. 5,714,350 and 6,350,861, the entire contents of each of which are incorporated herein by reference.
[0452] Additionally or alternatively, modified anti-IL1RAP antibodies can be prepared with altered glycosylation patterns, such as hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNAc structures. Such altered glycosylation patterns have been shown to increase the ADCC ability of antibodies. Such carbohydrate modifications can be achieved, for example, by expressing the antibody in a host cell with an altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells for expressing recombinant antibodies to produce antibodies with altered glycosylation. See, eg, Shields, RL et al., (2002) J. Biol. Chem. 277:26733-26740; Umana et al., (1999) Nat. Biotech. 17:176-1, and European Patent No. EP 1,176,195; PCT Publication Nos. WO 03 / 035835; WO 99 / 54342 80, the entire contents of each of which are incorporated herein by reference.
[0453] Protein glycosylation depends on the amino acid sequence of the target protein and the host cell in which the protein is expressed. Different organisms can produce different glycosylases (e.g., glycosyltransferases and glycosidases) and have available different substrates (nucleotide sugars). Due to these factors, the glycosylation pattern of the protein and the composition of the glycosyl residues may be different, depending on the host system in which the specific protein is expressed. Useful glycosyl residues can include but are not limited to glucose, galactose, mannose, fucose, n-acetylglucosamine and sialic acid. Preferably, the glycosylated binding protein comprises glycosyl residues so that the glycosylation pattern is human.
[0454] Different protein glycosylation can produce different protein characteristics. For example, the efficacy of therapeutic proteins glycosylated using the yeast endogenous pathway produced in microbial hosts (such as yeast) may be reduced compared to the same protein expressed in mammalian cells such as CHO cell lines. Such glycoproteins can also be immunogens in humans and show a reduced half-life in vivo after administration. Specific receptors in humans and other animals can recognize specific glycosyl residues and promote rapid clearance of proteins from the bloodstream. Other adverse effects may include changes in protein folding, solubility, sensitivity to proteases, transport, transportation, compartmentalization, secretion, recognition by other proteins or factors, antigenicity or allergenicity. Therefore, practitioners may prefer therapeutic proteins with specific glycosylation compositions and patterns, such as glycosylation compositions and patterns that are identical or at least similar to those produced in human cells or species-specific cells of the intended target animal.
[0455] Host cells can be genetically modified to express heterologous glycosylation enzymes to express glycosylated proteins that are different from those of the host cells. Using recombinant technology, practitioners can produce antibodies or antigen-binding portions thereof that show human protein glycosylation. For example, yeast strains have been genetically modified to express non-naturally occurring glycosylation enzymes so that the glycosylated proteins (glycoproteins) produced in these yeast strains show the same protein glycosylation as animal cells (particularly human cells) (U.S. Patent Publication Nos. 20040018590 and 20020137134 and PCT Publication WO2005100584 A2).
[0456] Antibodies can be produced by any of a variety of techniques. For example, from host cell expression, an expression vector encoding heavy and light chains is transfected into the host cell by standard techniques. The various forms of the term "transfection" are intended to encompass the various techniques typically used to introduce exogenous DNA into protokaryotic or eukaryotic host cells, such as electroporation, calcium phosphate precipitation, DEAE-dextran transfection, etc. Although antibodies can be expressed in protokaryotic or eukaryotic host cells, expressing antibodies in eukaryotic cells is preferred, and is most preferred in mammalian host cells, because such eukaryotic cells (and particularly mammalian cells) are more easily assembled and secrete antibodies that are suitably folded and immunocompetent than prokaryotic cells.
[0457] Preferred mammalian host cells for expressing the recombinant antibodies disclosed herein include Chinese hamster ovary (CHO) cells (including dhfr-CHO cells, described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77: 4216-4220, using a DFFR selective marker, such as described in RJ Kaufman and PA Sharp (1982) Mol. Biol. 159: 601-621), NSO melanoma cells, COS cells, and SP2 cells. When a recombinant expression vector encoding an antibody gene is introduced into a mammalian host cell, the antibody can be produced by culturing the host cell for a sufficient period of time to allow expression of the antibody in the host cell or, more preferably, secretion of the antibody into the culture medium in which the host cell is grown. The antibody can be recovered from the culture medium using standard protein purification methods.
[0458] Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be understood that variants of the above procedures are within the scope of the present disclosure. For example, it may be ideal to transfect host cells with DNA encoding antibody light chain and / or heavy chain functional fragments. Recombinant DNA technology can also be used to remove some or all of the DNA encoding one or both of the light or heavy chains that are unnecessary for binding to the antigen of interest. Molecules expressed by such truncated DNA molecules are also included in the antibodies of the present disclosure. In addition, bifunctional antibodies can be produced, in which one heavy chain and one light chain are antibodies of the present disclosure, while the other heavy chain and light chain have specificity for antigens other than the antigen of interest, which are formed by cross-linking the antibody of the present disclosure with a second antibody using standard chemical cross-linking methods.
[0459] In a preferred system for recombinant expression of antibodies or antigen-binding portions thereof, recombinant expression vectors encoding the antibody heavy chain and the antibody light chain are introduced into CHO cells containing a glutamine synthase expression system commercially available from Lonza (hereinafter referred to as GS-CHO) (Bebbington, CR et al., (1992), Biotechnology, 10, pp. 169-175).
[0460] In another system for recombinant expression of antibodies or antigen-binding portions thereof, recombinant expression vectors encoding the antibody heavy and light chains are introduced into dhfr-CHO cells via calcium phosphate-mediated transfection. Within the recombinant expression vector, both the antibody heavy and light chain genes are operably linked to CMV enhancer / AdMLP promoter regulatory elements to drive high levels of gene transcription. The recombinant expression vector also carries the DHFR gene, which allows selection / amplification using methotrexate to select CHO cells transfected with the vector. The selected transformed host cells are cultured to express the antibody heavy and light chains, and the intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select the transformants, culture the host cells, and recover the antibody from the culture medium. Furthermore, the present disclosure provides methods for synthesizing recombinant antibodies by culturing host cells in a suitable culture medium until the recombinant antibody is synthesized. Recombinant antibodies can be produced using nucleic acid molecules corresponding to the amino acid sequences disclosed herein. In one embodiment, the nucleic acid molecules set forth in SEQ ID NOs: 191-259 are used to produce the recombinant antibodies. The method can also include isolating the recombinant antibody from the culture medium. III. Anti-IL1RAP Antibody Drug Conjugate (ADC)
[0461] The anti-IL1RAP antibodies described herein can be conjugated to a drug moiety to form an anti-IL1RAP antibody drug conjugate (ADC). Antibody-drug conjugates (ADCs) can improve the therapeutic effectiveness of antibody-treated diseases (e.g., cancer) because the ADC can selectively deliver one or more drug moieties to target tissues or cells (e.g., tumors expressing IL1RAP or cells expressing IL1RAP). Thus, in certain embodiments, the present disclosure provides anti-IL1RAP ADCs for therapeutic use (e.g., treating cancer).
[0462] The anti-IL1RAP ADC comprises an anti-IL1RAP antibody (i.e., an antibody that specifically binds to IL1RAP) linked to one or more drug moieties. The specificity of the ADC is defined by the specificity of the antibody (i.e., anti-IL1RAP). In one embodiment, the anti-IL1RAP antibody is linked to one or more cytotoxic drugs, which are delivered to cancer cells expressing IL1RAP.
[0463] Provided below are examples of drugs that can be used in anti-IL1RAP ADCs, as well as linkers that can be used to conjugate antibodies to one or more drugs. The terms "drug," "agent," and "drug moiety" are used interchangeably herein. The terms "linked" and "conjugated" are also used interchangeably herein and indicate that the antibody and moiety are covalently linked.
[0464] In some embodiments, the ADC has the structure shown below (Formula I):
[0465] Ab-(LD) n (I)
[0466] Wherein Ab is an anti-IL1RAP antibody described herein, and (LD) is a linker-drug moiety. The linker-drug moiety consists of L- as a linker and -D as a drug moiety, the drug moiety having, for example, cell growth inhibition, cytotoxicity, or other therapeutic activity against target cells (e.g., cells expressing IL1RAP); and n is an integer from 1 to 20. In some embodiments, n ranges from 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or is 1. The DAR of the ADC is equivalent to "n" in Formula I.
[0467] Additional details regarding the drug (D in Formula I) and linker (L in Formula I) that can be used in the ADC, as well as alternative ADC structures, are described below.
[0468] A. Anti-IL1RAP ADC: Exemplary Drugs for Conjugation
[0469] Anti-IL1RAP antibodies can be used in ADCs to target one or more drugs to cells of interest (e.g., cells expressing IL1RAP). The anti-IL1RAP ADCs disclosed herein provide a targeted therapy that, for example, can reduce the side effects common to anticancer therapies when one or more drugs are delivered to specific cells. In one embodiment, the drug used in the ADC is saporin. In another embodiment, the drug used in the ADC is dacarbazine. In another embodiment, the drug used in the ADC is carboplatin.
[0470] Examples of drugs that can be used in ADCs, i.e., drugs that can be conjugated to anti-IL1RAP antibodies, are provided below and include mitotic inhibitors, antitumor antibiotics, immunomodulators, gene therapy vectors, alkylating agents, anti-angiogenic agents, antimetabolites, boron-containing agents, chemoprotectants, hormonal agents, glucocorticoids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, radiosensitizers, topoisomerase inhibitors, tyrosine kinase inhibitors, and combinations thereof.
[0471] 1. Mitosis inhibitors
[0472] In one aspect, an anti-IL1RAP antibody can be conjugated to one or more mitotic inhibitors to form an ADC for the treatment of cancer. As used herein, the term "mitotic inhibitor" refers to a cytotoxic and / or therapeutic agent that blocks mitosis or cell division, a biological process that is particularly important for cancer cells. Mitotic inhibitors destroy microtubules, thereby preventing cell division, typically by affecting microtubule polymerization (e.g., inhibiting microtubule polymerization) or microtubule depolymerization (e.g., stabilizing the microtubule cytoskeleton to prevent depolymerization). Thus, in one embodiment, an anti-IL1RAP antibody of the present invention is conjugated to one or more mitotic inhibitors that disrupt microtubule formation by inhibiting tubulin polymerization. In another embodiment, an anti-IL1RAP antibody of the present invention is conjugated to one or more mitotic inhibitors that stabilize the microtubule cytoskeleton to prevent depolymerization. In one embodiment, the mitotic inhibitor used in the ADC of the present invention is Ixempra (ixabepilone). Examples of mitotic inhibitors that can be used in the anti-IL1RAP ADC of the present invention are provided below. Included in the class of mitotic inhibitors are auristatins, as described below.
[0473] a. Dolastatin
[0474] The anti-IL1RAP antibodies of the present invention can be conjugated to at least one dolastatin to form an ADC. Dolastatin is a short peptide compound isolated from the Indian Ocean sea hare, Dolabella auricularia (see Pettit et al., J. Am. Chem. Soc., 1976, 98, 4677). Examples of dolastatin include dolastatin 10 and dolastatin 15. Dolastatin 15 (a 7-subunit depsipeptide from Dolabella auricularia) is a highly effective antimitotic agent that is structurally related to the anti-tubulin agent dolastatin 10 (a 5-subunit peptide obtained from the same organism). Thus, in one embodiment, the anti-IL1RAP ADC of the present invention comprises an anti-IL1RAP antibody as described herein and at least one dolastatin toxin. Auristatin is a synthetic derivative of dolastatin 10.
[0475] b. Auristatin
[0476] The anti-IL1RAP antibody can be conjugated to at least one auristatin. Auristatins represent a group of dolastatin analogs that have generally been shown to interfere with microtubule dynamics and GTP hydrolysis, thereby inhibiting cell division, and thus have anticancer activity. For example, auristatin E (U.S. Patent No. 5,635,483) is a synthetic analog of the marine natural product dolastatin 10, which inhibits tubulin polymerization by binding to the same site on tubulin as the anticancer drug vincristine (GRPettit, Prog. Chem. Org. Nat. Prod, 70: 1-79 (1997)). Dolastatin 10, auristatin PE, and auristatin E are linear peptides with four amino acids, three of which are unique to the dolastatin class of compounds. Exemplary embodiments of the auristatin subclass of mitotic inhibitors include, but are not limited to, monomethyl auristatin D (MMAD or auristatin D derivatives), monomethyl auristatin E (MMAE or auristatin E derivatives), monomethyl auristatin F (MMAF or auristatin F derivatives), auristatin F phenylenediamine (AFP), auristatin EB (AEB), auristatin EFP (AEFP) and 5-benzoylvaleric acid-AE ester (AEVB). These are disclosed in U.S. Patent Application Publication Nos. 2003-0083263, 2005-0238649 and 2005-0009751; International Patent Publication No. WO 04 / 010957, International Patent Publication No. WO The synthesis and structure of auristatin derivatives are described in US Pat. Nos. 02 / 088172; 02 / 088172 and U.S. Pat. Nos. 6,323,315; 6,239,104; 6,034,065; 5,780,588; 5,665,860; 5,663,149; 5,635,483; 5,599,902; 5,554,725; 5,530,097; 5,521,284; 5,504,191; 5,410,024; 5,138,036; 5,076,973; 4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,414, each of which is incorporated herein by reference.
[0477] In one embodiment, the anti-IL1RAP antibody is conjugated to at least one MMAE (monomethyl auristatin E). Monomethyl auristatin E (MMAE, vedotin) inhibits cell division by preventing the polymerization of tubulin. Due to its extremely strong toxicity, it cannot be used as a drug by itself. In recent cancer treatment developments, it is linked to a monoclonal antibody (mAb) that recognizes a specific marker expressed in cancer cells, and the MMAE is directed to the cancer cells. In one embodiment, the linker connecting MMAE to the anti-IL1RAP antibody is stable in the extracellular fluid (i.e., the culture medium or environment outside the cell), but once the ADC binds to a specific cancer cell antigen and enters the cancer cell, it is cleaved by cathepsins, thereby releasing the toxic MMAE and activating a highly effective anti-mitotic mechanism.
[0478] The structure of MMAE is provided below.
[0479]
[0480] In one embodiment, the antibody is conjugated to a single drug, and thus the DAR is 1. In certain embodiments, the ADC will have a DAR of 2 to 8, or alternatively 2 to 4. c. Maytansinoid
[0481] The anti-IL1RAP antibodies of the present invention can be conjugated to at least one maytansine alkaloid to form an ADC. Maytansine alkaloids are highly effective antitumor agents originally isolated from higher plants of the Celastraceae, Rhamnaceae, and Euphorbiaceae families, as well as some mosses (Kupchan, J. Am. Chem. Soc. 94: 1354-1356
[1972] ; Wani, J. Chem. Soc. Chem. Commun. 390:
[1973] ; Powell, J. Nat. Prod. 46: 660-666
[1983] ; Sakai, J. Nat. Prod. 51: 845-850
[1988] ; and Suwanborirux et al., Experientia 46: 117-120
[1990] ). There is evidence that maytansine alkaloids inhibit mitosis by inhibiting the tubulin polymerization of tubulin, thereby preventing the formation of microtubules (see, for example, U.S. Patent number 6,441,163 and Remillard et al., Science, 189,1002-1005 (1975)). Using cell culture models in vitro and using laboratory animal systems in vivo, it has been demonstrated that maytansine alkaloids inhibit tumor cell growth. Moreover, the cytotoxicity of maytansine alkaloids is 1,000 times (see, for example, U.S. Patent number 5,208,020) of conventional chemotherapeutic agents (such as, for example, methotrexate, daunorubicin and vincristine).
[0482] Maytansine alkaloids include C-3 esters of maytansine, maytansinol, maytansinol and other maytansinol analogs and derivatives (see, for example, U.S. Patent number 5,208,020 and 6,441,163, each of which is incorporated herein by reference). The C-3 ester of maytansinol can be naturally occurring or synthetically derived. Moreover, naturally occurring and synthetic C-3 maytansinol esters can be classified as C-3 esters with simple carboxylic acids, or with the C-3 esters of N-methyl-L-alanine derivatives, the latter having higher cytotoxicity than the former. For example, at Kupchan et al., J.Med.Chem., 21, the analogs of synthetic maytansine alkaloids are described in 31-37 (1978).
[0483] The suitable maytansine alkaloids used in the ADC of the present invention can be separated from natural sources, synthesized or semi-synthetically produced. Moreover, the maytansine alkaloids can be modified in any suitable manner, as long as enough cytotoxicity is retained in the final conjugate molecule. In this regard, the maytansine alkaloids lack the suitable functional groups that can be connected to the antibody. It is desirable to use a linking moiety to connect the maytansine alkaloids to the antibody to form a conjugate, and in the following joint chapters and sections, it is described in more detail. The structure of exemplary maytansine alkaloids mertansine (DM1) is hereinafter provided.
[0484]
[0485] Representative examples of maytansine alkaloids include, but are not limited to, DM1 (N 2 '-Deacetyl-N 2 '-(3-mercapto-1-oxopropyl)-maytansine; also known as mertansine, drug maytansine alkaloid 1; ImmunoGen, Inc.; see also Chari et al., (1992) Cancer Res 52:127), DM2, DM3 (N 2 '-Deacetyl-N 2 '-(4-mercapto-1-oxopentyl)-maytansine), DM4 (4-methyl-4-mercapto-1-oxopentyl)-maytansine), and maytansinol (a synthetic maytansine alkaloid analog). Other examples of maytansine alkaloids are described in U.S. Patent No. 8,142,784, which is incorporated herein.
[0486] Ansamitocin is a group of maytansine alkaloid antibiotics isolated from various bacterial sources. These compounds have potent anti-tumor activity. Representative examples include, but are not limited to, ansamitocin P1, ansamitocin P2, ansamitocin P3, and ansamitocin P4.
[0487] In one embodiment of the present invention, the anti-IL1RAP antibody is conjugated to at least one DM1. In one embodiment, the anti-IL1RAP antibody is conjugated to at least one DM2. In one embodiment, the anti-IL1RAP antibody is conjugated to at least one DM3. In one embodiment, the anti-IL1RAP antibody is conjugated to at least one DM4.
[0488] 2. Antitumor antibiotics
[0489] Anti-IL1RAP antibodies can be conjugated to one or more antitumor antibiotics for the treatment of cancer. As used herein, the term "antitumor antibiotic" refers to an antitumor drug that prevents cell growth by interfering with DNA and is made from microorganisms. Typically, antitumor antibiotics destroy DNA chains or slow down or stop DNA synthesis. Examples of antitumor antibiotics that can be included in anti-IL1RAP ADCs include, but are not limited to, actinomycins (e.g., pyrrolo[2,1-c][1,4]benzodiazepines), anthracyclines, calicheamicin, and dulcamycin. In addition to the above, other antitumor antibiotics that can be used in anti-IL1RAP ADCs include bleomycin (Blenoxane, Bristol-Myers Squibb), mitomycin, and plicamycin (also known as mithramycin).
[0490] 3. Immunomodulators
[0491] In one aspect, the anti-IL1RAP antibody can be conjugated to at least one immunomodulator. As used herein, the term "immunomodulator" refers to an agent that can stimulate or regulate an immune response. In one embodiment, the immunomodulator is an immunostimulator that enhances the immune response of the subject. In another embodiment, the immunomodulator is an immunosuppressant that prevents or reduces the immune response of the subject. The immunomodulator can regulate myeloid cells (monocytes, macrophages, dendritic cells, megakaryocytes and granulocytes) or lymphoid cells (T cells, B cells and natural killer (NK) cells) and any further differentiated cells thereof. Representative examples include, but are not limited to, Bacillus Calmette-Guérin (BCG) and levamisole (Ergamisol). Examples of other immunomodulators that can be used in ADC include, but are not limited to, cancer vaccines and cytokines.
[0492] As used herein, the term "cancer vaccine" refers to a composition (e.g., a tumor antigen and a cytokine) that stimulates a tumor-specific immune response. The immune response is stimulated by the subject's own immune system by administering a cancer vaccine or, in the case of the present disclosure, administering an ADC comprising an anti-IL1RAP antibody and a cancer vaccine. In a preferred embodiment, the immune response can eliminate tumor cells (e.g., primary or metastatic tumor cells) in the body. The use of cancer vaccines generally involves the administration of a specific antigen or group of antigens, which, for example, is present on the surface of a specific cancer cell, or on the surface of a specific pathogenic factor that has been shown to promote the formation of cancer. In some embodiments, the use of cancer vaccines is for preventive purposes, while in other embodiments, it is for therapeutic purposes. Non-limiting examples of cancer vaccines that can be used in anti-IL1RAP ADCs include recombinant bivalent human papillomavirus (HPV) vaccine types 16 and 18 (Cervarix, GlaxoSmithKline), recombinant quadrivalent human papillomavirus (HPV) vaccine types 6, 11, 16, and 18 (Gardasil, Merck & Company), and sipuleucel-T (Provenge, Dendreon). Thus, in one embodiment, the anti-IL1RAP antibody is conjugated to at least one cancer vaccine that is an immunostimulatory agent or an immunosuppressive agent.
[0493] Anti-IL1RAP antibodies can be conjugated to at least one cytokine. The term "cytokine" generally refers to a protein released by a cell population that acts on another cell as an intercellular mediator. Cytokines directly stimulate immune effector cells and stromal cells at the tumor site and enhance the recognition ability of tumor cells by cytotoxic effector cells (Lee and Margolin (2011) Cancers 3:3856). A large number of animal tumor model studies have shown that cytokines have a wide range of anti-tumor activities, which have been translated into a variety of cytokine-based cancer treatments (Lee and Margoli, supra). In recent years, a variety of cytokines including GM-CSF, IL-7, IL-12, IL-15, IL-18 and IL-21 have entered clinical trials for patients with advanced cancer (Lee and Margoli, supra).
[0494] Examples of cytokines that can be used in ADCs include, but are not limited to, parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones, such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor; Müllerian inhibitory substance; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factor, such as NGF; platelet-derived growth factor; transforming growth factor ( TGF); insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons, such as interferon α, β and γ; colony stimulating factor (CSF); granulocyte-macrophage-C-SF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (IL), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; tumor necrosis factor; and other polypeptide factors, including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of native sequence cytokines. Thus, in one embodiment, the present disclosure provides an ADC comprising an anti-IL1RAP antibody as described herein and a cytokine.
[0495] The anti-IL1RAP antibody can be conjugated to at least one colony stimulating factor (CSF). Colony stimulating factor (CSF) is a growth factor that helps the bone marrow produce red blood cells. Because certain cancer treatments (e.g., chemotherapy) affect white blood cells (which help fight infection), colony stimulating factors can be introduced to help support white blood cell levels and boost the immune system. Colony stimulating factors can also be used after a bone marrow transplant to help the new bone marrow begin to produce white blood cells. Representative examples of CSF that can be used in anti-IL1RAP ADCs include, but are not limited to, erythropoietin (Epoetin), filgrastim (also known as granulocyte colony stimulating factor (G-CSF); Amgen, Inc.), sargramostim (leukine (granulocyte-macrophage colony stimulating factor and GM-CSF); Genzyme Corporation), promegapoietin, and opreluekin (recombinant IL-11; Pfizer, Inc.). Thus, in one embodiment, an ADC can comprise an anti-IL1RAP antibody as described herein and a CSF.
[0496] 4. Alkylating agents
[0497] The anti-IL1RAP antibody can be conjugated to one or more alkylating agents. Alkylating agents are a class of anti-tumor compounds that attach alkyl groups to DNA. Examples of alkylating agents that can be used in ADCs include, but are not limited to, alkyl sulfonates, ethyleneimines, methylamine derivatives, epoxides, nitrogen mustards, nitrosoureas, triazines, and hydrazines.
[0498] 4. DNA-damaging agents
[0499] In one embodiment, the antibodies and antigen-binding portions thereof described herein can be conjugated to one or more DNA damaging agents. As used herein, the term "DNA damaging agent" refers to an agent that can damage DNA and is well known to those of ordinary skill in the art (see, for example, Cheung-Ong et al., Cell Chemical Biology, 20(5):648-659, 2013).
[0500] DNA damaging agents include DNA alkylating agents. DNA alkylating agents are a class of antitumor compounds that add alkyl groups (C n H 2n+1 ) attached to DNA. Examples of DNA alkylating agents that can be used in ADCs include, but are not limited to, alkyl sulfonates (e.g., busulfan), ethyleneimines (e.g., hexamethylmelamine and thiotepa), methylamine derivatives, epoxides, nitrogen mustards (e.g., bendamustine, chlorambucil, cyclophosphamide, ifosfamide, methoxyethylamine, melphalan), nitrosoureas (e.g., carmustine, lomustine, and streptozotocin), triazines (e.g., dacarbazine and temozolomide), and hydrazine.
[0501] DNA damaging agents also include indole-benzodiazepines (IGNs). IGNs represent a chemical class of cytotoxic molecules with high in vitro potency against cancer cells (IC 50 Values are in the lower pmol / L range). Examples of IGN DNA alkylating agents that can be used as cytotoxic payloads in ADCs are described in Miller et al. (2016) Molecular Cancer Therapeutics, 15(8). The IGN compounds described in Miller et al. bind to the minor groove of DNA, whereupon the guanine residues covalently react with two imine functional groups in the molecule, resulting in DNA crosslinking. The structure of an exemplary IGN is provided below.
[0502]
[0503] In one embodiment, the DNA damaging agent may further comprise a pyrrolobenzodiazepine (PBD) or a pyridobenzodiazepine (PDD) (see, e.g., N. Veillard et al., "Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity" [Abstract]. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research; 2018 Apr 14-18; Chicago, Illinois. Philadelphia (PA): AACR; 2018. Abstract No. 736 / 3 and Stefano JE et al., (2013) Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting. In: Ducry L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology (Methods and Protocols), vol 1045. Humana Press, Totowa, NJ)).
[0504] In another embodiment, the DNA damaging agent is a PARP inhibitor, such as olaparib, rucaparib, niraparib, or iniparib. In one embodiment, the PARP inhibitor is olaparib. In one embodiment, the PARP inhibitor is rucaparib. In one embodiment, the PARP inhibitor is niraparib. In one embodiment, the PARP inhibitor is iniparib. In one embodiment, the agent is a saporin toxin.
[0505] 5. Anti-angiogenic agents
[0506] In one aspect, an anti-IL1RAP antibody described herein is conjugated to at least one anti-angiogenic agent. Anti-angiogenic agents inhibit the growth of new blood vessels. Anti-angiogenic agents work in a variety of ways. In some embodiments, these agents interfere with the ability of growth factors to reach their targets. For example, vascular endothelial growth factor (VEGF) is one of the main proteins that triggers angiogenesis by binding to specific receptors on the cell surface. Thus, certain anti-angiogenic agents that prevent VEGF from interacting with its cognate receptors prevent VEGF from initiating angiogenesis. In other embodiments, these agents interfere with intracellular signaling cascades. For example, once a specific receptor on the cell surface is triggered, a series of other chemical signals are triggered to promote blood vessel growth. Therefore, certain enzymes known to promote intracellular signaling cascades (e.g., those that contribute to cell proliferation) (e.g., some tyrosine kinases) are targets for cancer treatment. In other embodiments, these agents interfere with intracellular signaling cascades. However, in other embodiments, these agents disable specific targets that activate and promote cell growth or directly interfere with vascular cell growth. More than 300 substances have been found to have angiogenesis inhibitory effects, with many direct and indirect inhibitory effects.
[0507] Representative examples of angiogenesis inhibitors that can be used in ADCs include, but are not limited to, angiostatin, ABXEGF, C1-1033, PKI-166, EGF vaccine, EKB-569, GW2016, ICR-62, EMD 55900, CP358, PD153035, AG1478, IMC-C225 (Erbitux), ZD1839 (Iressa), OSI-774, erlotinib (Tarceva), angiostatin, arrestin, endostatin, BAY 12-9566 combined with fluorouracil or doxorubicin, angiostatin, carboxyamidotriazole combined with paclitaxel, EMD121974, S-24, vitaxin, dimethylsulfonylquinone acetic acid, IM862, interleukin-12, interleukin-2, NM-3, HuMV833, PTK787, RhuMab, angiozyme, IMC-1C11, Neovastat, marimstat, pumastat, BMS-275291, COL-3 , MM1270, SU101, SU6668, SU11248, SU5416, in combination with paclitaxel, in combination with gemcitabine and cisplatin, in combination with irinotecan and cisplatin, and in combination with radiation, tecogalan, temozolomide and PEG interferon α2b, tetrathiomolybdate, TNP-470, thalidomide, CC-5013, and in combination with taxotere, tumor inhibitors, 2-methoxyestradiol, VEGF traps, mTOR inhibitors (rapamycin, everolimus (Afinitor, Novartis Pharmaceutical Corporation) and temsirolimus (Torisel, Pfizer, Inc.)), tyrosine kinase inhibitors (e.g., erlotinib (Tarceva, Genentech, Inc.), imatinib (Gleevec, Novartis Pharmaceutical Corporation), gefitinib (Iressa, AstraZeneca Pharmaceuticals), dasatinib (Ceramide, Brystol-Myers Squibb), sunitinib (Sutent, Pfizer, Inc.), nilotinib (Tasigna, Novartis Pharmaceutical Corporation), lapatinib (Tykerb, GlaxoSmithKline Pharmaceuticals), sorafenib (Nexavar, Bayer and Onyx)), phosphoinositide 3-kinase (PI3K).
[0508] 6. Antimetabolites
[0509] Anti-IL1RAP antibodies can be conjugated to at least one antimetabolite. Antimetabolites are a type of chemotherapy treatment that is very similar to normal substances in cells. When cells incorporate antimetabolites into cellular metabolism, the result is negative for the cells, for example, the cells cannot divide. Antimetabolites are classified according to the substance they interfere with. Examples of antimetabolites that can be used in ADCs include, but are not limited to, folic acid antagonists (e.g., methotrexate), pyrimidine antagonists (e.g., 5-fluorouracil, floxuridine, cytarabine, capecitabine, and gemcitabine), purine antagonists (e.g., 6-mercaptopurine and 6-thioguanine), and adenosine deaminase inhibitors (e.g., cladribine, fludarabine, nelarabine, and pentostatin), as described in more detail below.
[0510] 7. Boron-containing agents
[0511] The anti-IL1RAP antibody can be conjugated to at least one boron-containing agent. Boron-containing agents comprise a class of cancer therapeutic compounds that interfere with cell proliferation. Representative examples of boron-containing agents include, but are not limited to, borophycin and bortezomib (Velcade, Millenium Pharmaceuticals).
[0512] 8. Chemical protective agents
[0513] The anti-IL1RAP antibody can be conjugated to at least one chemoprotectant. Chemoprotectants are a class of compounds that can help protect the body from specific toxic effects of chemotherapy. Chemoprotectants can be administered with a variety of chemotherapies to protect healthy cells from the toxic effects of chemotherapy drugs while allowing cancer cells to be treated by the administered chemotherapy. Representative chemoprotectants include, but are not limited to, amifostine (Ethyol, Medimmune, Inc.), which is used to reduce the nephrotoxicity associated with the cumulative dose of cisplatin, dexrazoxane (Totect, Apricus Pharma; Zinecard), for the treatment of extravasation caused by the administration of anthracycline antibiotics (Totect), and for the treatment of heart-related complications caused by the administration of the antitumor antibiotic doxorubicin (Zinecard), and mesna (Mesnex, Bristol-Myers Squibb), which is used to prevent hemorrhagic cystitis during treatment with ifosfamide chemotherapy.
[0514] 9. Photoactive therapeutic agents
[0515] The anti-IL1RAP antibody can be conjugated to at least one photoactive therapeutic agent. Photoactive therapeutic agents include compounds that can be used to kill treated cells after exposure to electromagnetic radiation of a specific wavelength. Therapeutically relevant compounds absorb electromagnetic radiation of a wavelength that penetrates tissue. In preferred embodiments, the compound is administered in a non-toxic form that is capable of producing a photochemical effect that is toxic to cells or tissues upon sufficient activation. In other preferred embodiments, these compounds are retained in cancerous tissue and are readily cleared from normal tissue. Non-limiting examples include various chromatins and dyes.
[0516] 10. Radioactive nuclides (radioisotopes)
[0517] The anti-IL1RAP antibody can be conjugated to at least one radionuclide agent. Radionuclide agents include agents characterized by having an unstable nucleus that can undergo radioactive decay. The basis for successful radionuclide therapy depends on sufficient concentration and long-term retention of the radionuclide in cancer cells. Other factors to consider include the half-life of the radionuclide, the energy of the emitted particle, and the maximum range to which the emitted particle can propagate. In a preferred embodiment, the therapeutic agent is a radionuclide selected from the following: 111 In, 177 Lu, 212 Bi, 213 Bi, 211 At 62 Cu, 64 Cu, 67 Cu, 90 Y. I25 I. I31 I. 32 P. 33 P. 47 Sc, 111 Ag, 67 Ga, 142 Pr, 153 Sm, 161 Tb, 166 Dy, 166 Ho, 186 Re、 188 Re、 189 Re、 212 Pb, 223 Ra, 225 Ac, 59 Fe, 75 Se, 77 As、 89 Sr. 99 Mo, 105 Rh, I09 Pd, 143 Pr, 149 Pm,169 Second, 194 Ir, 198 Au, 199 Au and 211 Pb. It is also preferred to use radionuclides that substantially decay with Auger-emitting particles. Examples include Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt-109, In-111, Sb-119, I-125, Ho-161, Os-189m, and Ir-192. Useful beta-emitting nuclides preferably have decay energies of Dy-152, At-211, Bi-212, Ra-223, Rn-219, Po-215, Bi-211, Ac-225, Fr-221, At-217, Bi-213, and Fm-255. Useful alpha-emitting radionuclides preferably have decay energies of 2,000-10,000 keV, more preferably 3,000-8,000 keV and most preferably 4,000-7,000 keV. Other radioisotopes that may be used include 11 C. 13 N. 15 0. 75 Br, 198 Au, 224 Ac, 126 I. 133 I. 77 Br, 113m In, 95 Such as 97 Such as I03 Such as 105 Such as 107 Hg, 203 Hg, 121m Te, 122m Te, 125m Te, 165 Tm, I67 Tm, 168 Tm, 197 Pt, 109 Pd, 105 Rh, 142 Pr, 143 Pr, 161 Tb, !66 Ho, 199 Au, 57 Co、 58 Co、 51 Cr, 59 Fe, 75 Se, 201 Tl, 225 Ac, 76 Br, I69 Yb et al.
[0518] 11. Radiosensitizers
[0519] Anti-IL1RAP antibodies can be conjugated to at least one radiosensitizer. As used herein, the term "radiosensitizer" is defined as a molecule (preferably a low molecular weight molecule) administered to an animal in a therapeutically effective amount to increase the sensitivity of radiosensitized cells to electromagnetic radiation and / or promote the treatment of diseases that can be treated with electromagnetic radiation. Radiosensitizers are agents that make cancer cells more sensitive to radiotherapy while generally having much less effect on normal cells. Thus, radiosensitizers can be used in combination with radiolabeled antibodies or ADCs. The addition of a radiosensitizer can result in enhanced efficacy compared to treatment with radiolabeled antibodies or antibody fragments alone. Radiosensitizers are described in DM Goldberg (ed.), Cancer Therapy with Radiolabeled Antibodies, CRC Press (1995). Examples of radiosensitizers include gemcitabine, 5-fluorouracil, taxanes, and cisplatin.
[0520] Radiosensitizers can be activated by electromagnetic radiation of X-rays. Representative examples of radiosensitizers activated by X-rays include, but are not limited to, the following: metronidazole, misomidazole, demethylimidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FUdR), hydroxyurea, cisplatin, and analogs and derivatives thereof that are effective for treatment. Alternatively, photodynamic therapy (PDT) can be used to activate radiosensitizers. Representative examples of photodynamic radiosensitizers include, but are not limited to, hematoporphyrin derivatives, photofrin (r), benzoporphyrin derivatives, NPe6, tin protoporphyrin (SnET2), pheophorbide a, bacteriochlorophyll a, naphthalocyanine, phthalocyanine, zinc phthalocyanine, and analogs and derivatives thereof that are effective for treatment.
[0521] 12. Topoisomerase inhibitors
[0522] Anti-IL1RAP antibodies can be conjugated to at least one topoisomerase inhibitor. Topoisomerase inhibitors are chemotherapeutic agents designed to interfere with topoisomerases (topoisomerases I and II), which are enzymes that control changes in DNA structure during the normal cell cycle by catalyzing, then breaking and reconnecting the phosphodiester backbone of the DNA chain. Representative examples of DNA topoisomerase I include, but are not limited to, camptothecin and its derivatives irinotecan (CPT-11, Camptosar, Pfizer, Inc.) and topotecan (Hycamtin, GlaxoSmithKline Pharmaceuticals). Representative examples of DNA topoisomerase II include, but are not limited to, amsacrine, daunorubicin, doxorubicin, epipodophyllotoxin, ellipticine, epirubicin, etoposide, razoxane, and teniposide.
[0523] 13. Tyrosine kinase inhibitors
[0524] Anti-IL1RAP antibodies can be conjugated to at least one tyrosine kinase inhibitor. Tyrosine kinases are enzymes within cells that attach phosphate groups to the amino acid tyrosine. By blocking the function of protein tyrosine kinases, tumor growth can be inhibited. Examples of tyrosine kinases that can be used in ADCs include, but are not limited to, axitinib, bosutinib, cediranib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, semaxanib, sunitinib, and vandetanib.
[0525] 14. Other medicines
[0526] Examples of other agents that can be used in ADCs include, but are not limited to, abrin (e.g., abrin A chain), alpha toxin, oleone protein, amatoxin, crotin, curcin, dianthin protein, cholera toxin (e.g., cholera toxin A chain and non-binding active fragments of cholera toxin), deoxyribonuclease (DNase), gelonin, milin, modeccin A chain, momordica charantia inhibitor, neomycin, ranpimerase, phenomycin, pokeweed proteins (PAPI, PAPII, and PAP-S), pokeweed antiviral protein, Pseudomonas endotoxin, Pseudomonas exotoxin (e.g., exotoxin A chain (from Pseudomonas aeruginosa)), restrictocin, ricin A chain, ribonuclease (RNase), saponin inhibitor, saporin, alpha sarcin, Staphylococcal enterotoxin-A, tetanus toxin, cisplatin, carboplatin, and oxaliplatin (Eloxatin, Sanofi Aventis), proteasome inhibitors (e.g., PS-341 [bortezomib or Velcade]), HDAC inhibitors (vorinostat (Zolinza, Merck & Company, Inc.), belinostat, entinostat, moxistat, and panobinostat), COX-2 inhibitors, substituted ureas, heat shock protein inhibitors (e.g., geldanamycin and its various analogs), adrenocortical suppressants, and trichothecenes. (See, e.g., WO 93 / 21232). Other agents include asparaginase (Espar, Lundbeck Inc.), hydroxyurea, levamisole, mitotane (Lysodren, Bristol-Myers Squibb), and tretinoin (Renova, Valeant Pharmaceuticals Inc.).
[0527] It should be noted that the above group of drug moieties that can be used in anti-IL1RAP ADCs is not exclusive, as some examples of drugs can be in more than one class, e.g., ansamitocin is both a mitotic inhibitor and an antitumor antibiotic.
[0528] All stereoisomers of the above-described drug moieties are contemplated for use herein, ie, any combination of R and S configurations at the chiral carbons of D.
[0529] The above-described agents (i.e., naked agents not conjugated to antibodies) can also be used in combination therapy with the anti-IL1RAP antibodies described herein. In one embodiment, the anti-IL1RAP antibody or ADC is used in combination therapy with any of the aforementioned agents to treat cancer, wherein the agent is administered before, simultaneously with, or after the anti-IL1RAP antibody or ADC is administered to the subject.
[0530] B. Anti-IL1RAP ADC: Exemplary Linkers
[0531] The anti-IL1RAP ADC comprises an anti-IL1RAP antibody and at least one drug, wherein the antibody and at least one drug are conjugated via a linker. As used herein, the term "linker" refers to a chemical moiety, which may be bifunctional or multifunctional, that is used to connect the antibody to the drug moiety. The linker may comprise one conjugated component or may comprise multiple components.
[0532] For example, a linker may comprise a spacer, which is a moiety that extends the drug attachment, to avoid, for example, shielding the active site of an antibody or to improve the solubility of an ADC. Other examples of components of a linker include a Stretcher unit and an Amino Acid unit.
[0533] Two approaches are commonly used to conjugate drugs to antibodies: alkylation of reduced interchain cysteine disulfide bonds via enzymatically non-cleavable maleimides or simple and cleavable disulfide linkers, and acylation of lysines via cleavable linear amino acids.
[0534] In one aspect, the linker covalently attaches the antibody to the drug moiety. ADCs are prepared using a linker having a reactive functional group for connecting the antibody to the drug. For example, a cysteine thiol or amine (e.g., N-terminus or amino acid side chain, such as lysine) of the antibody can form a bond with the functional group of the linker.
[0535] In one aspect, the linker has a functional group that can react with the free cysteine present on the antibody to form a covalent bond. Non-limiting examples of such reactive functional groups include maleimide, haloacetamide, α-haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acyl chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. See, for example, Klussman et al., (2004), Bioconjugate Chemistry 15(4): p. 766 of 765-773 for conjugation methods.
[0536] In some embodiments, the linker has a functional group that can react with an electrophilic group present on the antibody. Examples of such electrophilic groups include, but are not limited to, aldehydes and ketone carbonyls. In some embodiments, the heteroatom of the reactive functional group of the linker can react with the electrophilic group on the antibody and form a covalent bond with the antibody unit. Non-limiting examples of such reactive functional groups include, but are not limited to, hydrazides, oximes, amino groups, hydrazines, thiosemicarbazones, benzyl hydrazinecarboxylate, and arylhydrazides.
[0537] Suitable linkers include, for example, cleavable and non-cleavable linkers. The linker can be a "cleavable linker" to facilitate the release of the drug. Non-limiting exemplary cleavable linkers include acid-labile linkers (for example, comprising hydrazones), protease-sensitive (for example, peptidase-sensitive) linkers, photolabile linkers or disulfide-bonded linkers (Chari et al., Cancer Research 52: 127-131 (1992); U.S. Patent number 5,208,020). Cleavable linkers are generally easy to cleave under intracellular conditions. Suitable cleavable linkers include, for example, peptide linkers that can be cleaved by intracellular proteases such as lysosomal proteases or endosomal proteases. In exemplary embodiments, the linker can be a dipeptide linker, such as valine-citrulline (val-cit) or phenylalanine-lysine (phe-lys) linkers.
[0538] The linker is preferably stable outside the cell in a manner sufficient to be therapeutically effective. Prior to transport or delivery into the cell, the ADC is preferably stable and remains intact, i.e., the antibody remains conjugated to the drug moiety. A linker that is stable outside the target cell can be cleaved at an effective rate once inside the cell. Thus, an effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow delivery of the drug moiety, e.g., intracellular delivery; and (iii) maintain the therapeutic effect of the drug moiety, e.g., cytotoxic effect.
[0539] In one embodiment, the joint is cleavable under intracellular conditions so that the cracking of the joint fully releases the drug from the antibody in the intracellular environment, thereby having a therapeutic effect. In some embodiments, the cleavable joint is pH-sensitive, i.e., sensitive to hydrolysis under certain pH values. Typically, pH-sensitive joints are hydrolyzable under acidic conditions. Typically, pH-sensitive joints are hydrolyzable under acidic conditions. For example, acid-labile joints (e.g., hydrazones, semicarbazones, thiosemicarbazones, cis-aconitamides, orthoesters, acetals, ketals, etc.) that are hydrolyzable in lysosomes can be used. (See, e.g., U.S. Patent Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661.) Such linkers are generally relatively stable under neutral pH conditions, such as those in blood, but are unstable below pH 5.5 or 5.0 (the approximate pH of lysosomes). In certain embodiments, the hydrolyzable linker is a thiol ether linker (such as, for example, a thiol ether attached to the therapeutic agent via an acylhydrazone bond (see, e.g., U.S. Patent No. 5,622,929)).
[0540] In other embodiments, the linker is cleavable under reducing conditions (e.g., a disulfide linker). A variety of disulfide linkers are well known in the art, including, for example, those that can be formed using SATA (N-succinimidyl-5-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio) propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio) butyrate), and SMPT (N-succinimidyloxycarbonyl-α-methyl-α-(2-pyridyl-dithio) toluene), SPDB, and SMPT. (See, e.g., Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer C. W. Vogeled., Oxford U. Press, 1987. See also U.S. Pat. No. 4,880,935.).
[0541] In some embodiments, the linker is cleavable by a cleavage agent (e.g., an enzyme) present in the intracellular environment (e.g., within a lysosome or endosome or caveolae). The linker can be, for example, a peptidyl linker that is cleaved by an intracellular peptidase or protease (including but not limited to a lysosomal or endosomal protease). In some embodiments, the peptidyl linker is at least two amino acids long or at least three amino acids long. Cleavage agents can include cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives, thereby releasing the active drug within the target cell (see, e.g., Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). The most typical is a peptidyl linker that is cleavable by an enzyme present in cells expressing IL1RAP. Examples of such linkers are described, for example, in U.S. Patent No. 6,214,345, which is incorporated herein by reference in its entirety for various purposes. In a specific embodiment, the peptidyl linker that can be cleaved by intracellular proteases is a Val-Cit linker or a Phe-Lys linker (see, e.g., U.S. Patent No. 6,214,345, which describes the synthesis of doxorubicin with a val-cit linker). One advantage of using intracellular proteolytic release of the therapeutic agent is that the agent is attenuated when conjugated and the serum stability of the conjugate is generally higher.
[0542] In other embodiments, the linker is a malonate linker (Johnson et al., 1995, Anticancer Res. 15: 1387-93), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1299-1304), or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1305-12).
[0543] In yet other embodiments, the linker unit is non-cleavable and releases the drug, for example, by degradation of the antibody. See U.S. Publication No. 20050238649, the entire contents of which are incorporated herein by reference. ADCs comprising non-cleavable linkers can be designed so that the ADC remains essentially extracellular and interacts with certain receptors on the surface of the target cell so that binding of the ADC activates (or blocks) a specific cell signaling pathway.
[0544] In some embodiments, the linker is a substantially hydrophilic linker (e.g., PEG4Mal and Sulfo-SPDB). Hydrophilic linkers can be used to reduce the extent to which drugs are pumped out of drug-resistant cancer cells via MDR (multidrug resistance) or functionally similar transporters.
[0545] In other embodiments, after cleavage, the linker directly or indirectly inhibits cell growth and / or cell proliferation. For example, in some embodiments, the linker can act as an intercalating agent after cleavage, thereby inhibiting the biosynthesis of macromolecules (e.g., DNA replication, RNA transcription and / or protein synthesis).
[0546] In other embodiments, the linker is designed to promote bystander killing (killing of neighboring cells) by allowing diffusion of the linker-drug and / or drug alone to neighboring cells. In other embodiments, the linker promotes cellular internalization.
[0547] The presence of sterically hindered disulfide bonds can increase the stability of specific disulfide bonds, thereby enhancing the efficacy of ADCs. Thus, in one embodiment, the linker comprises a sterically hindered disulfide bond. A sterically hindered disulfide bond refers to a disulfide bond that exists within a specific molecular environment, wherein the environment is characterized by a specific spatial arrangement or orientation of atoms, typically within the same molecule or compound, that prevents or at least partially inhibits the reduction of the disulfide bond. Thus, the presence of macromolecular (or sterically hindered) chemical moieties and / or macromolecular amino acid side chains in proximity to the disulfide bond prevents or at least partially inhibits potential interactions of the disulfide bond, which would lead to the reduction of the disulfide bond.
[0548] It is worth noting that the aforementioned linker types are not mutually exclusive. For example, in one embodiment, the linker used in the anti-IL1RAP ADC described herein is a non-cleavable linker that promotes cellular internalization.
[0549] In some embodiments, the ADC has the structure shown in the following formula (Formula I):
[0550] Ab-(LD) n (I)
[0551] or a pharmaceutically acceptable salt or solvate thereof; wherein Ab is an antibody, such as an anti-IL1RAP antibody, and (LD) is a linker-drug moiety. The linker-drug moiety is composed of L- as a linker and -D as a drug moiety, the drug moiety having, for example, cell growth inhibition, cytotoxicity, or other therapeutic activity against target cells (e.g., cells expressing IL1RAP); and n is an integer from 1 to 20.
[0552] In some embodiments, n ranges from 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or is 1.
[0553] In some embodiments, the -D moieties are identical. In yet another embodiment, the -D moieties are different.
[0554] In some embodiments, the linker component comprises an "amino acid unit". In some such embodiments, the amino acid unit allows the linker to be cleaved by proteases, thereby promoting the release of the drug from the immunoconjugate after exposure to intracellular proteases (such as lysosomal enzymes) (Doronina et al., (2003) Nat. Biotechnol. 21: 778-784). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). The amino acid unit may comprise naturally occurring amino acid residues and / or minor amino acids and / or non-naturally occurring amino acid analogs, such as citrulline. The amino acid unit may be designed and optimized to be cleaved by specific enzymes (e.g., tumor-associated proteases, cathepsins B, C and D or plasmin proteases).
[0555] In one embodiment, the amino acid unit is valine-citrulline (vc or val-cit). In another aspect, the amino acid unit is phenylalanine-lysine (i.e., fk). In another aspect of the amino acid unit, the amino acid unit is N-methyl valine-citrulline. In another aspect, the amino acid unit is 5-aminovaleric acid, all-phenylalanine lysine, tetraisoquinoline carboxylic acid lysine, cyclohexylalanine lysine, isopentazoline lysine, β-alanine lysine, glycine serine valine glutamine and isopentazoline.
[0556] Another approach for generating ADCs involves the use of heterobifunctional cross-linkers to link the anti-IL1RAP antibody to the drug moiety. Examples of cross-linkers that can be used include N-succinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate or the highly water-soluble analogs N-sulfosuccinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate, N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), N-succinimidyl-4-(5-nitro-2-pyridyldithio)butyrate (SNPB), and N-sulfosuccinimidyl- 4-(5-nitro-2-pyridyldithio)butyrate (SSNPB), N-succinimidyl-4-methyl-4-(5-nitro-2-pyridyldithio)pentanoate (SMNP), N-succinimidyl-4-(5-N,N-dimethylcarboxamido-2-pyridyldithio)butyrate (SCPB), or N-sulfosuccinimidyl-4-(5-N,N-dimethylcarboxamido-2-pyridyldithio)butyrate (SSCPB). Antibodies can be modified with the cross-linkers N-succinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate, N-sulfosuccinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate, SPDB, SNPB, SSNPB, SMNP, SCPB, or SSCPB and then reacted with a slight excess of a particular drug containing a sulfhydryl moiety to obtain good ADC yields (see also U.S. Pat. No. 6,913,748, which is incorporated herein by reference).
[0557] In one embodiment, a charged linker (also known as a proto-charged linker) is used to conjugate an anti-IL1RAP antibody to a drug to form an ADC. Charged linkers include linkers that become charged after cellular processing. The presence of one or more charged groups in the linker or on the drug of a particular ADC after cellular processing has many advantages, such as (i) high...
Claims
1. An anti-IL1RAP antibody or an antigen-binding portion thereof, wherein the anti-IL1RAP antibody or the antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 11, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 10, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 16, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 15, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 14; The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 51, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 50, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 49, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 55, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 54, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 53; The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 59, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 58, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 57, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 63, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 61; or The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 176, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 175, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 174, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 179, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 178, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
79.
2. The antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof is of the IgG isotype.
3. The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof has a K of 200 nM or less. D .
4. An anti-IL1RAP antibody or an antigen-binding portion thereof, wherein the anti-IL1RAP antibody or the antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:82; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:48 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:52; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60; or A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:173 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
177.
5. An isolated nucleic acid encoding the antibody or antigen-binding portion thereof of claim 1.
6. A pharmaceutical composition comprising the antibody or antigen-binding portion thereof according to claim 1, and a pharmaceutically acceptable carrier.
7. The antibody, or antigen binding portion thereof, of claim 1, wherein the anti-IL1RAP antibody, or antigen binding portion thereof, is conjugated to at least one drug.
8. The antibody or antigen binding portion thereof of claim 7, wherein the at least one drug is selected from the group consisting of DNA damaging agents, anti-apoptotic agents, mitotic inhibitors, anti-tumor antibiotics, immunomodulators, anti-angiogenic agents, antimetabolites, boron-containing agents, chemoprotectants, hormone agents, anti-hormones, photoactive therapeutic agents, oligonucleotides, radionuclide agents, radiosensitizers, topoisomerase inhibitors, and tyrosine kinase inhibitors.
9. The antibody or antigen binding portion thereof of claim 8, wherein the oligonucleotide is a nucleic acid for gene therapy and the hormonal agent is a corticosteroid.
10. The antibody, or antigen binding portion thereof, of claim 7, wherein the at least one drug is conjugated to the antibody, or antigen binding portion thereof, via a linker.
11. The antibody or antigen binding portion thereof of claim 10, wherein the linker is a cleavable linker.
12. The antibody, or antigen binding portion thereof, of claim 10, wherein the linker is a non-cleavable linker.
13. An antibody drug conjugate (ADC) comprising an antibody or antigen binding portion thereof conjugated to at least one drug, wherein the antibody or antigen binding portion thereof comprises a heavy chain variable region and a light chain variable region, The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 11, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 10, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 16, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 15, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 14; The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 51, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 50, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 49, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 55, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 54, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 53; The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 59, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 58, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 57, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 63, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 61; or The heavy chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 176, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 175, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 174, and the light chain variable region comprises a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 179, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 178, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
79.
14. The ADC of claim 13, wherein the antibody or antigen binding portion thereof is of IgG1 isotype or IgG4 isotype.
15. The ADC of claim 13, wherein the average drug to antibody ratio (DAR) of the ADC is 1 to 8.
16. Use of the antibody or antigen binding portion thereof of any one of claims 1-4, or the ADC of any one of claims 13-15, in the preparation of a medicament for treating cancer, wherein the cancer is acute myeloid leukemia (AML).
